

MAHARASHTRA MEDICAL GOODS PROCUREMENT AUTHORITY

Expression of Interest (EOI) for Market Assessment of Original Manufacturers and Authorized Importers for Supply of Tablets and Capsules (Year 2026-27)

**EOI reference No: E-283/MMGPA/ EOI for Tablets and Capsules
(2026-27)**

1st Floor, Aarogya Bhawan St. George's Hospital Compound,
Near C.S.M.T. Railway Station, Mumbai - 400 001.
Maharashtra

Website: <http://mahatenders.gov.in>

Email: maha.mmghpa2023@gmail.com Phone : 022-22717527

Table of Contents

Table of Contents.....	2
Disclaimer	4
Abbreviations and Glossary	6
Notice and Schedule Inviting Expression of Interest (EOI)	7
EOI Notice	7
Section 1: Introduction	8
Section 2: General Definitions	9
Section 3: General Terms and Conditions	10
3.1 Responsibility of verification of contents of EOI	10
3.2 Acknowledgement of the Responder	10
3.3 Period of Validity of EOI	10
3.4 Nature of the Expression of Interest.....	10
3.5 Responsibility of EOI Respondents	11
3.6 Submission of EOI Responses	11
3.7 Clarifications and Amendments.....	11
3.8 Conflict of Interest	12
3.9 Fraudulent and Corrupt Practices.....	12
3.10 Confidentiality	12
3.11 Governing Law	12
3.12 Respondents Information	12
3.13 Manufacturing/Importing and Product Permissions	14
3.14 Delivery Capability	14
3.15 Respondent Classification.....	15
3.16 Eligibility Criteria	15
Appendix A: Schedule of Requirements	23
Appendix B: Checklist	64
Annexure 1: Technical Specifications and Compliance	66
Annexure-2: Undertaking by EoI Respondent	68
Annexure-3: Proforma for Production and Sale Statement	70
Annexure 4: Details of Manufacturing Unit.....	71
Annexure-4 (A): Proof of Distribution Network.....	74
Annexure-5: Details of Items Quoted with Drug Code	75
Annexure 6: Annual Turnover Statement for Three Years	76
Annexure-7: Format for Power of Attorney for signing of EOI.....	78

Annexure-8: Undertaking for Non-blacklisting	80
Annexure- 9: Litigation Affidavit.....	81
Annexure-10: Litigation Affidavit.....	82
Annexure 11: Delivery and Supply Capability.....	83
Annexure 11 (a) : Delivery Acceptance Certificate.....	84
Annexure 12: Respondent Classification Details	85

Disclaimer

This Expression of Interest (EOI) Document is not an agreement and is neither an offer nor invitation by the MMGPA to the prospective EOI Responders or any other person. The purpose of this Expression of Interest (EOI) Document is to invite interested and eligible entities to provide information relating to their regulatory status, manufacturing capability, quality systems, market presence, and related parameters, solely to enable MMGPA to undertake a market assessment and planning exercise in connection with any potential future procurement of Tablets and Capsules.

This Expression of Interest (EOI) Document contains information, statements, and indicative details prepared by MMGPA solely for the purpose of facilitating a broad market assessment and planning exercise in relation to the potential future procurement of Tablets and Capsules. Such information and statements are based on assumptions, preliminary assessments, and internal considerations and are not intended to be exhaustive or definitive. This EOI Document may not address the specific circumstances, operational capacities, or regulatory positions of every interested entity, and MMGPA, its employees, or advisors do not undertake to consider the individual requirements of each person or entity reviewing or responding to this document. The information provided herein may be subject to change and may not be complete, accurate, or current in all respects. Each EOI Respondent is therefore advised to conduct its own assessment, verification, and analysis of the information contained in this EOI Document and to seek independent professional or technical advice as it considers appropriate.

Information provided in this Expression of Interest (EOI) Document to the EOI Responder(s) is on a wide range of matters, some of which may depend upon interpretation of law. The information given is not intended to be an exhaustive account of statutory requirements and should not be regarded as a complete or authoritative statement of law. The MMGPA accepts no responsibility for the accuracy or otherwise for any interpretation or opinion on law expressed herein.

The MMGPA, its employees and advisors make no representation or warranty and shall have no liability to any person, including any EOI Responder(s) under any law, statute, rules or regulations or tort, principles of restitution or unjust enrichment or otherwise for any loss, damages, cost or expense which may arise from or be incurred or suffered on account of anything contained in this Expression of Interest (EOI) Document or otherwise, including the accuracy, adequacy, correctness, completeness or reliability of the Expression of Interest (EOI) Document and any assessment, assumption, statement or information contained therein or deemed to form part of this Expression of Interest (EOI) Document or arising in any way for participation in this Expression of Interest (EOI) Document.

The MMGPA may, in its absolute discretion but without being under any obligation to do so, update, amend or supplement the information, assessment or assumptions contained in this Expression of Interest (EOI) Document.

The EOI Responder(s) shall bear all its costs associated with or relating to the preparation and submission of its EOI Response including but not limited to preparation, copying, postage, delivery fees, expenses associated with any demonstrations or presentations which may be required by the MMGPA, or any other costs incurred in connection with or relating to its EOI Response. All such costs and expenses will remain with the EOI Responder(s) and the MMGPA shall not be liable in any manner whatsoever for the same or for any other costs or other expenses incurred by a EOI Responder(s) in preparation or submission of the EOI Response, regardless of the conduct or outcome of the responding process. The MMGPA also accepts no liability of any nature whether resulting from negligence or otherwise howsoever caused arising from reliance of any EOI Responder(s) upon the statements contained in this Expression of Interest (EOI) Document.

MMGPA shall not be responsible or liable for any costs, expenses, or losses incurred by EOI Respondents in connection with preparation or submission of EOI Responses, regardless of the outcome of the EOI process. Participation in this Expression of Interest (EOI) shall not confer any right or entitlement on the EOI Respondents to participate in any subsequent procurement process.

MMGPA reserves the right to independently determine the eligibility criteria, qualification requirements, and procurement strategy in any future tender process, without any reference to or obligation arising from this EOI.

Abbreviations and Glossary

Abbreviations	Description
BET	Bacterial Endotoxin Test
BIS	Bureau of Indian Standards
BP	British Pharmacopeia
CA	Chartered Accountant
CLA	Central Level Authority
COPP	Certificate of Pharmaceutical Products
CT	Clinical Trials
DCGI	Drug Controller General of India
DMER	Directorate of Medical Education & Research
DPCO	Drug Price Control Order
DPIIT	Department for Promotion of Industry and Internal Trade
ESIC	Employees State Insurance Corporation
FDA	Food and Drug Administration
FEMA	Foreign Exchange Management Act 1999
GMP	Good Manufacturing Practices
G.R.	Government Resolution
GST	Goods and Services Tax
GS1	Global Standards1
HBPCL	Haffkine Bio-Pharmaceutical Corporation Limited
IEC	Import Export Code
IP	Indian Pharmacopeia
ISI	Indian Standards Institute
I.V.	Intra Venous
LLP	Limited Liability Partnership
MCGM	Municipal Corporation of Greater Mumbai
MDR	Medical Device Rules
MMGPA	Maharashtra Medical Goods Procurement Authority
MRP	Maximum Retail Price
MSC	Market Standing Certificate
MSEs	Micro and Small Enterprises
NABL	National Accreditation Board for Laboratories
NSQ	Not of Standard Quality
NPPA	National Pharmaceutical Pricing Authority
OEM	Original Equipment Manufacturer
PAN	Permanent Account Number
PoA	Power of Attorney
PVC	Poly Vinyl Chloride
PVdC	Poly Vinylidene Chloride
SLA	State Level Authority
SSI	Small Scale Industries
UDIN	Unique Document Identification Number
USP	United States Pharmacopeia
WHO	World Health Organization

Notice and Schedule Inviting Expression of Interest (EOI)

EOI Notice

The Maharashtra Medical Goods Procurement Authority (MMGPA) invites Expressions of Interest (EOI) from eligible Original Manufacturers (OEMs) and their Authorized Importers for assessing market capability, regulatory compliance, manufacturing capacity, and delivery capability for supply of Tablets and Capsules to public health institutions in the State of Maharashtra.

This EOI is a non-binding, pre-procurement exercise and does not constitute a tender or offer of contract. No price submissions, financial offers, or securities are required at this stage.

The objective of this EOI is to assess the number of eligible and capable OEMs and Authorized Importers available for the listed Tablets and Capsules and their readiness to participate in future procurement processes.

The information collected through this EOI will be used for planning future procurement strategies. MMGPA reserves the right to initiate or not initiate any subsequent tender or rate contract process without any obligation to the EOI respondents.

Only Original Manufacturers or their Authorized Importers are eligible to participate. Traders, distributors, and other intermediaries are not permitted.

Interested entities meeting the eligibility conditions are invited to submit their EOI responses within the timelines specified in this document.

EOI responses must be submitted within fifteen (15) days from the date of publication of this EOI. Late submissions shall not be accepted.

All response-related activities, including downloading of documents and submission of responses, shall be governed by the schedule indicated below.

EOI Response Schedule

No.	Activity	Date & Time
1	Publication of Notice Inviting Expression of Interest (EOI)	From 27.05.2026 , 11:00 AM
2	Last date and time for submission of EOI Responses	dt.10.06.2026 at 3:00 PM
3	Opening of EOI Responses (Technical & capability only, No price information shall be submitted)	dt. 11.06.2026 at 3:00 PM
4	EoI Clarification Meeting	From 03.06.2026 , 02:00 PM
5	Address for communication	Meeting Hall, 1st Floor, Aarogya Bhawan, St. Georges Hospital Compound, Near CSMT Railway Station, Mumbai- 400 001

Sd/-

CHIEF EXECUTIVE OFFICER,
MAHARASHTRA MEDICAL GOODS
PROCUREMENT AUTHORITY

Section 1: Introduction

Maharashtra Medical Goods Procurement Authority (MMGPA), Mumbai has been formed as per the Maharashtra Medical Goods Procurement Authority Act 2023 (Mah. Act No. XIII of 2023) (“Act”).

MMGPA works as a single point procurement authority of certain medical goods and execution of turnkey projects with highest standards of transparency, fairness, equity and for timely supply at optimum and uniform rates and of desired quality and quantity for the Public Health Department, Medical Education & Drug Department of Government of Maharashtra and other departments as mentioned in the said Act.

To meet the objective of the Act, MMGPA in exercise of its powers under section 36 of the Act issued the regulations named, Maharashtra Medical Goods Procurement Authority Regulations, 2025 as amended from time to time.

- 1.1 All related activities (process) like EOI downloading and response submission will be governed by the EOI Schedule.
- 1.2 All activities of this EOI are carried out online on website <https://mahatenders.gov.in>. The EOI is uploaded on Government of Maharashtra, (GoM) e-tendering website <https://mahatenders.gov.in> and has to be downloaded as well as filled up and submitted online only.
- 1.3 No commitment is made by MMGPA regarding procurement of any quantity pursuant to this EOI, and the Authority reserves the right to modify, expand, curtail, or altogether omit any items or quantities in any subsequent procurement process, if undertaken
- 1.4 EOI process related Queries can be sent on email – eproc.support@maharashtra.gov.in /Help: The 24 x 7 Toll Free Telephonic Help Desk Number 1800-3070-2232. / Mobile: +91-7878107985, +91-7878107986, +91-7878007972 and +91-7878007973.

Sd/-
CHIEF EXECUTIVE OFFICER,
MAHARASHTRA MEDICAL GOODS
PROCUREMENT AUTHORITY
MUMBAI

Section 2: General Definitions

For the purposes of this Expression of Interest (EOI) Document, and unless the context otherwise requires, the following terms shall have the meanings assigned to them below:

- 2.1 **“Applicable Laws”** Means all laws, statutes, rules, regulations, notifications, guidelines, and policies in force in India as issued by the Government of India or the Government of Maharashtra, including but not limited to the Drugs and Cosmetics Act, 1940 and Rules thereunder, Medical Device Rules, 2017, New Drugs and Clinical Trials Rules, 2019, NPPA/DPCO provisions, and other applicable regulatory requirements, as amended from time to time.
- 2.2 **“Authority” or “MMGPA”** Means the Maharashtra Medical Goods Procurement Authority, established under the Maharashtra Medical Goods Procurement Authority Act, 2023.
- 2.3 **“Expression of Interest” or “EOI”** Means this non-binding, pre-procurement process initiated by MMGPA to solicit information regarding market capability, regulatory compliance, manufacturing capacity, and quality systems from eligible entities.
- 2.4 **“EOI Document”** Means this document, including all sections, appendices, annexures (if any), and amendments issued by MMGPA in connection with the Expression of Interest.
- 2.5 **“EOI Response”** Means the information and declarations submitted by an EOI Respondent in response to this EOI Document, limited to technical, regulatory, manufacturing, and capability-related information.
- 2.6 **“EOI Respondent”** Means any manufacturer or importer who submits an EOI Response pursuant to this EOI Document.
- 2.7 **“Conflict of Interest”** Means any situation in which an EOI Respondent has interests that could improperly influence its participation in the EOI process, including but not limited to relationships that compromise fairness, transparency, or objectivity.
- 2.8 **“Fraudulent or Corrupt Practices”** Means misrepresentation, concealment of facts, submission of false or forged documents, or any attempt to influence the EOI process improperly.
- 2.9 **“Government”** Means the Government of India or the Government of Maharashtra, as applicable.

Interpretation Words and expressions used but not defined in this EOI Document shall have the meanings assigned to them under Applicable Laws.

Note: The words and expressions used in this EOI, but not defined, shall have the same meaning as respectively assigned to them under the prevailing Applicable Laws.

Section 3: General Terms and Conditions

This section deals with the general conditions of the EOI and contains the following terms & conditions governing the EOI.

3.1 Responsibility of verification of contents of EOI

- 3.1.1 It shall be the responsibility of the EOI Responders to read/examine all instructions, forms, terms, conditions, specifications, schedules, appendix, annexures and other provisions contained in the Expression of Interest (EOI) Document, including any addendum or corrigendum issued thereunder prior to submission of the response.
- 3.1.2 Responders shall ensure that all required documents as specified in **Appendix A (Checklist)** are duly uploaded.

3.2 Acknowledgement of the Responder

- 3.2.1 It shall be deemed that by submitting the EOI, the Responder has:
- i. examined the EOI Document and understood its contents.
 - ii. received all relevant information available from MMGPA
 - iii. acknowledged and agreed that inadequacy, lack of completeness or incorrectness of information provided in the Expression of Interest (EOI) Documents shall not be a basis for any claim for compensation, damages or extension of time.
 - iv. acknowledged that it does not have a Conflict of Interest as per Clause 3.9 and
 - v. agreed to be bound by the provisions and undertakings provided by it under and in terms hereof.

MMGPA shall not be liable for any omission, mistake or error in respect of any of the above or on account of any matter or thing arising out of or concerning or relating to the EOI or its Responding process, including any error or mistake therein or in any information or data given by MMGPA.

3.3 Period of Validity of EOI

- 3.3.1 The EOI Response submitted pursuant to this document shall remain valid for the purpose of this EOI process only until completion of the EOI exercise or initiation of any subsequent procurement process, whichever is earlier.

3.4 Nature of the Expression of Interest

- 3.4.1 The information received pursuant to this EOI shall be used by MMGPA only for:
- a) market assessment and planning,
 - b) identification of technically and regulatorily suitable entities, and
 - c) formulation of future procurement strategies, if any.
- 3.4.2 This Expression of Interest (EOI) is a non-binding, pre-procurement exercise issued solely for the purpose of assessing market capability, regulatory compliance, manufacturing capacity, and quality systems of eligible entities.
- 3.4.3 Submission of an EOI Response does not constitute a bid, tender, or offer, and does not create any contractual, financial, or legal obligation on either MMGPA or the EOI Respondent.

- 3.4.4 MMGPA reserves the right to initiate or not initiate any subsequent procurement process, including a tender or RFP, without assigning any reason.
- 3.4.5 The EOI is intended to assess the number of eligible and capable Original Manufacturers and Authorized Importers available for each essential medicine/item and their readiness to participate in future procurement processes.

3.5 Responsibility of EOI Respondents

- 3.5.1 Each EOI Respondent shall:
- a) carefully examine the EOI Document and all instructions therein;
 - b) ensure that all information and documents submitted are true, accurate, and complete to the best of its knowledge;
 - c) satisfy itself regarding the scope, intent, and implications of the EOI.
 - d) Any misrepresentation, concealment, or submission of false information may result in rejection of the EOI Response.
- 3.5.2 Respondents shall provide accurate information regarding:
- (a) availability of medicines/item(s) against the provided list,
 - (b) manufacturing/import capacity,
 - (c) indicative delivery timelines.

3.6 Submission of EOI Responses

- 3.6.1 EOI Responses must be submitted within fifteen (15) days from the date of publication of the EOI. Late submissions shall not be accepted.
- 3.6.2 The EOI Response shall be limited to technical, regulatory, manufacturing, and capability-related information only.
- 3.6.3 No price bids, financial offers, bid securities, earnest money deposits, or payments of any kind are required or permitted at the EOI stage.

3.7 Clarifications and Amendments

- 3.7.1 EOI Respondents may seek clarification, within the timelines specified in the EOI Schedule.
- 3.7.2 MMGPA may, at its discretion:
- a) **issue clarifications,**
 - b) **amend the EOI Document, or**
 - c) **modify the EOI Schedule.**
- 3.7.3 All such clarifications or amendments shall form an integral part of the EOI Document.

3.8 Conflict of Interest

- 3.8.1 EOI Respondents shall disclose any actual or potential conflict of interest that may affect their participation in the EOI process.
- 3.8.2 MMGPA reserves the right to reject an EOI Response where a conflict of interest is found to compromise fairness, transparency, or objectivity.

3.9 Fraudulent and Corrupt Practices

- 3.9.1 EOI Respondents shall observe the highest ethical standards during the EOI process.
- 3.9.2 Any attempt to:
- a) misrepresent facts,
 - b) submit forged or misleading documents, or
 - c) improperly influence the EOI process
- 3.9.3 may result in rejection of the EOI Response and may render the entity ineligible for participation in future EOIs issued by MMGPA.

3.10 Confidentiality

- 3.10.1 Information submitted by EOI Respondents shall be treated as confidential to the extent permitted under applicable laws.
- 3.10.2 MMGPA may disclose such information where required by law, regulation, or directions of statutory or judicial authorities.

3.11 Governing Law

This EOI process shall be governed by and construed in accordance with the laws of India.

3.12 Respondents Information

Sr. No.	Document Name / Requirement	Description
1	Drug Manufacturing License	The manufacturing premises of the EOI Respondent 's products must comply with the requirements laid down under Schedule M of the Drugs and Cosmetics Rules, 1945. The EOI Respondent shall submit a valid compliance certificate/license issued by the State Licensing Authority unequivocally indicating Revised and upgraded Schedule M compliance as per GSR 922 (E), dated 28.12.2023. Attested photocopy of valid manufacturing drug license with product list approved by Central/State Licensing

Sr. No.	Document Name / Requirement	Description
		Authority for each and every product quoted as per technical specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license. If quoted item is manufactured at different places, Manufacturing License & Performance certificate from all such places from respective Licensing Authority/ State Drug Authority should be enclosed. However, Loan Licensee/ third party licensee are not allowed.
2	WHO-GMP Certificate	WHO-GMP certificate (with product list or COPP) clearly highlighting quoted products.
3	DCGI Permission	Copy of permission from DCGI for “New Drug & Fixed Dose Combination”.
4	Market Standing Certificate	Market Standing Certificate valid for a period of 5 years (i.e., for financial year 2021-22, 2022-23, 2023-24, 2024-25 & 2025-26) as a manufacturer/importer for each drug(s) quoted in the tender within the Bid Due date. The period of Market Standing will be reckoned from the date of issue of Product permission. In case of an importer, their principal manufacturer located overseas should have 5 years market standing in India and the importer shall have 5 years market standing in the pharmaceutical field. In cases involving new drugs/ drugs out of patent period it is sufficient to possess relevant market standing certificate, as applicable.
5	GST Registration	GST Registration certificate along with copy of last quarter.
6	Incorporation/Registration Certificate	Certificate of Incorporation / Registration of the EOI Respondent .
7	Authorization Letter	Authorization nominating responsible person to attend pre-bid/negotiation meetings.
8	Appendix-A	Schedule of Requirements.
9	Appendix-B	Checklist.
10	Annexure-1	Technical Specifications and Compliance.
11	Annexure-2	Letter Comprising Technical Bid.
12	Annexure-3	Proforma for Production and Sale Statement.
13	Annexure-4	Details of Manufacturing Unit.
13	Annexure-5	Details of Items Quoted with Drug Code.

Sr. No.	Document Name / Requirement	Description
15	Annexure-6	Annual Turnover Statement for three years (2022-23, 2023-24, and 2024-25) along with audited Balance Sheet & P&L Accounts for last 3 years certified by Statutory Auditor/Chartered Accountant with UDIN.
16	Annexure-7	Format of Power of Attorney for signing of Bid (not required for proprietorship).
17	Annexure-8	Affidavit for Non- Blacklisting.
18	Annexure-9	Litigation Affidavit.
19	Annexure-10	Mandate Form.
20	Schedule-4	Schedule for Packing of Drugs and Medicines.
21	Schedule-5	Bar Code & Advance Shipment Notification details.

3.13 Manufacturing/Importing and Product Permissions

- 3.13.1 EOI Respondents shall furnish details of their regulatory status as pharmaceutical manufacturers and/or importers licensed under the provisions of the Drugs and Cosmetics Act, 1940 and the rules made thereunder. Such details may include manufacturing licenses issued by the competent State Licensing Authority (SLA) and/or Central Licensing Authority (CLA), including licenses in Forms 25, 28, 28D, 28E, MD-5, and MD-9, as applicable to the drugs proposed, together with validity or retention particulars.
- 3.13.2 In the case of importers, Respondents shall furnish details of import licenses issued by the Drugs Controller General of India (DCGI), including Forms 10 or 10-A, along with relevant import registrations such as Form 41 or Form MD-15, and associated wholesale licenses such as Forms 20B and/or 21B, wherever applicable.
- 3.13.3 In respect of New Drugs and/or Fixed Dose Combinations, Respondents shall furnish details of import and/or manufacturing permissions obtained under the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019, including permissions such as Forms CT-20 and/or CT-23, where applicable.
- 3.13.4 In case of imported products, only one authorized importer per Original Manufacturer per product shall be permitted.
- 3.13.5 Respondents shall also indicate linkage between manufacturing/import approvals and supply capability, including delivery timelines.

3.14 Delivery Capability

- 3.14.1 EOI Respondents shall provide indicative details on:
- (a) production lead time,
 - (b) dispatch timeline,
 - (c) emergency supply capability,

- (d) monthly production capacity,
- (e) warehousing/logistics arrangements in Maharashtra.

3.15 Respondent Classification

3.15.1 EOI Respondents shall provide information on:

- (a) MSME status,
- (b) SC/ST ownership,
- (c) location – within Maharashtra / outside Maharashtra.

3.16 Eligibility Criteria

Sr.No.	Basic Requirement	Specific Requirement	Documents required
1	Registered Legal Entity	The EOI Respondent may be a company or a firm, registered under applicable laws in India (“Respondent”). The Respondent shall be – a. A Private Limited Company or a section 8 Company registered under the Companies Act 1956/2013, b. A Limited Liability Partnership under the Limited Liability Partnership Act 2008 c. Registered with the GST Authorities. d. Should have a valid PAN/TAN number. Proprietorship firms are not allowed to participate in this EOI.	Copy of certificate of incorporation/registration along with charter documents like copy of Memorandum and Articles of Association, and other registration documents according to the nature of entity. Copy of GST Registration certificate issued by GSTN authorities. Copy of PAN/TAN Card.
2	Licenses	The Respondent must have valid manufacturing license/import license for the drugs quoted as per technical specifications in the Tender Documents:	Self-attested copies of original manufacturing license in Form 25, 28, 28-D, 28-E, MD-5, MD-9 etc. approved by the Licensing authority along

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		a. Only manufacturer/ importer (i.e., authorized agent/subsidiary of the foreign manufacturer) will be allowed as Bidder. b. Loan Licensee / third party licensee are not permitted to participate under this Tender Document.	with retention Licenses. Or Self-attested copies of original import license in Form-10 or Form 10-A (as applicable), Form-41, MD-15 etc., and licenses in Form 20B/21B approved by the corresponding licensing authority with retention licenses. Or Self-attested copies of licenses in Form CT-20, Form CT-23 in case of new drugs. Further, during supply of drugs, if the drugs are manufactured at more than one premises, the Bidder shall submit the applicable license such as the manufacturing license, for each such premises mandatorily. Authority letter of the original manufacturer for importing the product for which bid is offered or agreement between foreign manufacturer and importer. The drugs quoted shall be highlighted in the product permission with their respective drug code as mentioned in the Appendix-A (Schedule of Requirement)

Sr.No.	Basic Requirement	Specific Requirement	Documents required
3	Certifications/Registration	WHO-GMP (WHO - Good Manufacturing Practices Certificate) Certificate issued by the licensing authority. The WHO-GMP certificate must not be older than one year from the Bid Due Date in case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Importer should produce WHO-GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted. The manufacturing premises of the Bidder's products must comply with the requirements laid down under Schedule M of the Drugs and Cosmetics Rules, 1945. The bidder shall submit a valid compliance certificate/license issued by the State Licensing Authority unequivocally indicating Revised and upgraded Schedule M compliance as per GSR 922 (E), dated 28.12.2023.	For manufacturers, WHO-GMP certificate with product list OR COPP, Quality management System (QMS) as per Medical Devices Rules, 2017 issued by the licensing authority wherever applicable. For importers, labels and product literature of all quoted drug(s) must be uploaded with WHO-GMP or certificate which is at par with WHO-GMP issued by the authorities of exporting countries of their principal manufacturing company or firm. Authority letter from OEM for the offered drug and valid import license issued by licensing authority. Import Export Certificate (IEC Code) for importer.
4	Past Experience	The Respondent must submit particulars of quantity of the past supplies of drugs made as per Annexure 3. Note: At least 80% quantity for similar drug as specified in the Schedule of	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-3)

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		Requirements i.e. Appendix A' must have been supplied for any of the last 3 (three) financial years preceding the Bid Due Date, i.e., 2023-24, 2024- 25 & 2025-26. The Respondent shall submit the work done with satisfaction from the concerned authority. For the Purpose of quantification of 80% similar work only the Purchase order from Govt./Semi-Govt.& Hospitals registered under Maharashtra Public Trust Act 1950 shall be considered. Purchase Order from private hospitals shall not be considered.	
5	Average Annual Turnover	Average Annual Turnover (in last three financial years 2023-24, 2024- 25 & 2025-26. shall be as per mentioned in the Schedule of Requirements i.e. Appendix A.	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-6) along with audited financial statements confirming the average annual Turnover of the Bidder during the stated financial years must be submitted. The turnover should be as certified by the chartered accountant/statutory auditor (specifying UDIN) and having valid registration. Note: In case the annual accounts for the latest financial year are not audited and therefore the Bidder cannot make it available, the Bidder shall

Sr.No.	Basic Requirement	Specific Requirement	Documents required
			give an undertaking to this effect and the chartered accountant/statutory auditor shall certify the same. In such a case, the Bidder shall provide the audited financial statements for the financial year preceding the latest financial year for which the audited annual report is not being provided.
6	Net Worth	The net worth of the Bidder in the financial year immediately preceding the Bid Due date should be positive and should have not eroded by more than 30% (thirty percent) in the last three (3) years.	Certificate issued by a statutory auditor/chartered accountant (as attached Annexure-6). The Net Worth should be as certified by the chartered accountant/ statutory auditor (specifying UDIN) and having valid registration.
7	Production Capacity	Production capacity of the original drug manufacturer must be minimum Two (2) times of the quoted order quantity in last one financial year.	Certificate of Statutory Auditor/Chartered Accountant. As per Annexure 4.
8	Market Standing Certificate	Bidder should mandatorily possess 5 years Market Standing Certificate (i.e., for financial year (2021-22, 2022-23, 2023-24, 2024-25 & 2025-26) as a manufacturer/importer for each drug(s) quoted in the tender as on Bid Due Date. The period of Market Standing will be reckoned from the date of issue of product/drug permission.	Market Standing Certificate as issued by Central or State Licensing Authority under the Applicable Law. Bill of landing of a foreign manufacturer and bill of entry of the importer, mentioning the country of

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		In case of an importer, their principal manufacturer located overseas should have 5 years market standing in India and the importer shall have 5 years market standing in the pharmaceutical field. In cases involving new drugs/ drugs out of patent period it is sufficient to possess relevant market standing as applicable.	origin. Notarized/ certified copy of Drug Controller General of India, new Delhi, for permission for Items coming under, “New Drug and Fixed Dose Combinations” in form 45/46 as per Drugs & Cosmetic Act and Rules. Relevant period Market standing certificate for new drug/drugs out of patent period issued by licensing authority.
9	Proof of distribution network	Bidders, if not having their registered office, manufacturing unit, or distribution facility within Maharashtra State, must have an established and operational distribution network in Maharashtra State at the time of EOI submission. In case there is no registered office or established operational distribution network the respondent/bidder shall give undertaking for establishment of both within three (3) months from the last date of submission of EOI.	Proof of distribution network— such as a valid drug selling/distribution license issued by the state’s licensing authority, along with details of authorized distributors (names, addresses, contact details) must be submitted as part of the bid documentation Annexure 4 (A) and Copy of License of Sale / Distribution issued by State’s Licensing Authority
10	Blacklisting or banned	On the Bid Due Date, the Bidder should not be blacklisted or debarred by any ministry/department /attached offices/sub-ordinate offices under Government of	Affidavit as per Annexure 8

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		India and any State government, Autonomous bodies (established by Central/State govt), any Central/State PSUs for unsatisfactory past performance, corrupt, fraudulent or any other Fraudulent and Corrupt business practices. The bidder, whose drug has been declared as misbranded, spurious or adulterated or any criminal case in respect of the above is pending in any court, as on Bid Due Date shall not be eligible to participate for that particular drug, in the bid. Similarly, a Bidder convicted by court of law shall not be eligible to participate in the bid.	
11	Non-Conviction Certificate	The Tenderer(s) quoting for this tender shall not have been convicted by any Court of Law in India/overseas in lieu of deficiency noticed in the any of the quoted Product(s) in the tender and tender should not be submitted for such products for which conviction was granted by any Court of Law for a period of Three years from date of such order(s).	Non-Conviction certificate Issued by licensing authority/State FDA.
12	Litigation	The Bidder should not be involved in any major litigation such as fraud, FEMA violations and any other civil or criminal proceedings that may have an impact of	Affidavit as per Annexure 9.

Sr.No.	Basic Requirement	Specific Requirement	Documents required
		affecting or compromising the delivery of services as required under this contract.	
13	Conflict of Interest	On the date of submission of the Bid, the Bidder should not have any conflict-of-interest situation.	Undertaking by the authorized signatory as per Annexure 2
14	Quantity specified in EOI	The quantity mentioned in the EOI is indicative in nature. Detail requirement will be given in subsequent RFP.	-

Appendix A: Schedule of Requirements

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
1	2 ACT (Adult) (Artesunate (A)+Sulphadoxine - Pyremethamine (B))	WHITE COLOR Total dose of Artesunate – 600 mg divided over three days, Sulphadoxine pyremethamine – (1500 +75)mg single dose Each Combi Blister Pack containing 3 Tablets of Artesunate (each 200 mg) and 2 Tablets of Sulphadoxine Pyremethamine (750+37.5)mg each or 3 Tablets of Sulphadoxine Pyremethamine (500+25) mg each Each row –No. of Tablets: First Row (Day 1): one Tablet of Artesunate (200 mg) and two Tablets of Sulphadoxine pyremethamine (750+37.5) mg each or three Tablets of Sulphadoxine Pyremethamine (500+25) mg each Second Row (Day 2) one Tablet of Artesunate (200mg) Third Row (Day 3): one Tablet of Artesunate (200 mg) - for adults i.e. 15 years & above Tablet Artesunate: Two years Tablet Sulfadoxine+Pyremethamine two years. Each Pack will bear shelf life of 2 years on the pack with manufacturing and expiry date	Tablet	59967	2398680
2	3 ACT (0 -- 1 years) (Artesunate (A)+Sulphadoxine - Pyremethamine (B))	PINK COLOR Total dose of Artesunate – 75 mg divided over three days, Sulphadoxine pyremethamine (250 mg + 12.5mg) single dose Each Combi Blister Pack : containing 3 Tablet of Artesunate (each Tablet of Artesunate 25mg strength) and 1 Tablet of Sulphadoxine Pyremethamine (250 mg + 12.5 mg) Each row – No. of Tablets: First Row (Day 1): One Tablet of Artesunate (25 mg) and one Tablet of Suphadoxine-Pyremethamine ((250 mg + 12.5	Tablet	5967	119340

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
		mg) Second Row (Day 2): one Tablet of Artesunate (25 mg) Third Row (Day 3): one Tablet of Artesunate (25 mg) CAUTION: The blister should be superscribed that SP is not to be given to children under 5 months and should be treated with alternate ACTs. Tablet Artesunate: Two years Tablet Sulfadoxine+Pyremethamine two years. Each Pack will bear shelf life of 2 years on the pack with manufacturing and expiry date.			
3	4 ACT (1 -- 4 years) (Artesunate (A)+Sulphadoxine - Pyremethamine (B))	YELLOW COLOR Total dose of Artesunate – 150 mg divided over three days, Sulphadoxine pyremethamine – (500+ 25)mg single dose Each Combi Blister Pack : containing 3 Tablets of Artesunate (50 mg each) and 1 Tablet of Sulphadoxine Pyremethamine (500+25)mg Each row – No. of Tablets: First Row (Day 1): One Tablet of Artesunate (50 mg) and One Tablet of Sulphadoxine Pyremethamine (500+25)mg Second Row(Day 2):One Tablet of Artesunate (50 mg) Third Row (Day 3): One Tablet of Artesunate (50mg) - for age group 1-4 years Tablet Artesunate: Two years Tablet Sulfadoxine+Pyremethamine two years. Each Pack will bear shelf life of 2 years on the pack with manufacturing and expiry date.	Tablet	59967	1410424
4	5 ACT (5 -- 8 years) (Artesunate (A)+Sulphadoxine - Pyremethamine (B))	GREEN COLOR Total dose of Artesunate – 300 mg divided over three days, Sulphadoxine pyremethamine (750 +37.5) mg single dose Each Combi Blister Pack	Tablet	59967	1914147

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
		containing 3 Tablets of Artesunate (100mg each) and 1 Tablet of Sulphadoxine Pyremethamine (750+ 37.5) mg Each row – No. of Tablets: First Row (Day 1): one Tablet of Artesunate (100mg) and one Tablet of sulphadoxine Pyremethamine (750mg+ 37.5) mg Second Row(Day 2):one Tablet of Artesunate (100mg) Third Row (Day 3): one Tablet of Artesunate (100mg) - for age group 5-8 yearsTablet Artesunate: Two years Tablet Sulfadoxine+Pyremethamine two years. Each Pack will bear shelf life of 2 years on the pack with manufacturing and expiry date.			
5	6 ACT (9 -- 14 years) (Artesunate (A)+Sulphadoxine - Pyremethamine (B))	RED COLOR Total dose of Artesunate – 450 mg divided over three days, Sulphadoxine pyremethamine (1000 +50) mg single dose Each Combi Blister Pack containing 3 Tablets of Artesunate 150 mg and 2 Tablets of Sulfadoxine Pyremethamine (500mg+ 25mg) Each row –No. of Tablets First Row (Day 1): One Tablets of Artesunate (150 mg) and two Tablets of Sulphadoxine Pyremethamine 500+25 mg) mg each Second Row(Day 2): One Tablet of Artesunate (150 g) Third Row (Day 3): One Tablet of Artesunate (150 mg) - for age group 9-14 yearsTablet Artesunate: Two years Tablet Sulfadoxine+Pyremethamine two years. Each Pack will bear shelf life of 2 years on the pack with manufacturing and expiry date.	Tablet	59967	2782469

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
6	Abacavir Tablet 300 mg	Each Abacavir 300 mg, contains: Abacavir 300 mg., Strip of 10 Tablet	Tablet	8910	21384
7	Aceclofenac & Tizanidine Tab	Each Tab/Cap to contain: Aceclofenac 100mg + Tizanidine 2mg	Tablet	4500	10152
8	Acetazolamide 250 mg Tab	Acetazolamide 250 mg Tab	Tablet	531900	589345
9	Acetyl Salicylic Acid (Aspirin)Tab 300 mg	Acetyl Salicylic Acid 300mg. Contains, Acetyl Salicylic Acid 300mg. Each, Strip of 10 Tablets	Tablet	1351271	1297220
10	Acetyl Salicylic acid 150 mg Enteric Coated Tab	Acetyl Salicylic acid 150 mg Enteric Coated Tab	Tablet	1260000	433440
11	Acetyl Salicylic Acid Tab. 150mg I.P	Acetyl Salicylic Acid 150mg. Contains, Acetyl Salicylic Acid 150mg. Each, Strip of 10 Tablets	Tablet	16078500	12862800
12	Acetyl Salicylic Acid Tab. 75mg I.P	Acetyl Salicylic Acid 75mg. Contains, Acetyl Salicylic Acid 75mg. Each, Strip of 10 Tablets	Tablet	58308300	15626624
13	Acetylsalicylic acid (Aspirin)Tab 25 mg	Acetyl Salicylic Acid 25mg. Contains, Acetyl Salicylic Acid 25mg. Each, Strip of 10 Tablets	Tablet	8910	4277
14	Acetylsalicylic Acid Tablet 50 mg	Acetylsalicylic Acid Tablet 50 mg	Tablet	8910	1433
15	Acyclovir 200 mg Tab	Acyclovir 200 mg Tab	Tablet	15750	28647
16	Acyclovir Tablet 200 mg (Store tablets protected from light)	Acyclovir Tablet 200 mg (Store tablets protected from light)	Tablet	8910	8554
17	Acyclovir Tablet 400mg	Acyclovir 400 mg Tab	Tablet	62775	158193
18	Acyclovir Tablet 800mg	Tablet Acyclovir 800 mg contains Acyclovir 800mg Each, Strip of 10 Tablets	Tablet	335093	696992
19	Acyclovir Tablet D T 200mg	Dispersible Tablet Acyclovir 200 mg contains Dispersible Acyclovir 200mg Each, Strip of 10 Tablets	Tablet	548910	1317384
20	Allopurinol Tab I.P 100mg	Tablet Allopurinol 100 mg, Each Tablet contains Allopurinol 100 mg., Strip of 10 Tablets	Tablet	35910	201096
21	Allopurinol Tablet 300 mg	Tablet Allopurinol 300 mg, Each Tablet contains Allopurinol 300 mg., Strip of 10 Tablets	Tablet	8910	57024
22	All-Trans Retinoic Acid Capsule 10mg	All Trans Retinoic Acid (Tretinoin) Soft Gelatin Capsule contains; All Trans Retinoic Acid	Capsule	89100	2851200

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
		(Tretinoin) USP 10 mg, Bottle 100 Soft Gelatin Capsules			
23	Alprazolam 0.25mg	Tab. Alprazolam 0.25mg., Each Tablets contains Alprazolam 0.25 mg, Strip of 10 Tablets	Tablet	645926	392723
24	Alprazolam Tablet 0.5 mg	Tab. Alprazolam 0.5mg., Each Tablets contains Alprazolam 0.5 mg, Strip of 10 Tablets	Tablet	2060910	1648728
25	Ambroxol and Terbutaline Tab	Each Uncoated Tab/Cap to contain: Ambroxol Hydrochloride 30 mg, Terbutaline Sulphate Equivalent to Terbutaline 2.5 mg	Tablet	56250	116550
26	Ambroxol Hcl+N- Acetyl-L-Cysteine Tab	Each Tab/Cap to contain: Ambroxol Hydrochloride 30 mg, N - Acetyl - L - Cysteine 200 mg,	Tablet	11250	22680
27	Amidarone Tab 100 mg	Amiodarone 100 mg Tab	Tablet	19125	62424
28	Amidarone Tab 200 mg	Amiodarone 200 mg Tab	Tablet	3375	21816
29	Amino acids and Multi Vitamin Capsules	Each Tab/Cap to contain: L- Arginine Hydrochloride USP 13.28mg, L-Histidine Hydrochloride H2O BP 3.71mg, L-Isoleucine USP 5.9mg, L- Leucine USP 18.3mg, L-Lysine Hydrochloride USP 25.0mg, DL- Methionine BP 18.4mg, L- Phenylalanine USP 5mg, L- Threonine USP 4.2mg, L- Tryptophan USP 5mg, L-Valine USP 6.7mg, 5-Hydroxy Anthranilic Acid HCL 0.2mg, Cholecalciferol IP 200 IU, Nicotinamide IP 25mg, Pyridoxine Hydrochloride IP 1.5mg, Methylcobalamin 500mcg, Biotin USP 30mcg, Folic Acid IP 0.75mg, Copper Sulphate BP 4mg, Ferrous Sulphate IP 20.5mg, Magnesium Sulphate IP 7.43mg, Manganese Sulphate BP 1.4mg, Potassium Iodide IP 0.1mg, Sodium Selenite BP 10.0mcg, Zinc Sulphate IP 15mg, Chromium Polynicotinate 200mcg	Capsule	28125	181125

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
30	Amiodarone Tab. 100mg	Tablet Amidarone 100 mg., Each Tablet contains; Amidorane 100 mg, Strip of 10 Tablets	Tablet	51840	186624
31	Amisulpride 50 mg Tablet	Amisulpride 50 mg Tablet	Tablet	1000	1680
32	Amitriptyline Tablet 10 mg	Tab. Amitryptillin hydrochloride 10 mg. FC, Strip of 10 Tablets	Tablet	16282080	21557474
33	Amitriptyline Tablet 25 mg	Tab. Amitryptillin hydrochloride 25 mg. FC, Strip of 10 Tablets	Tablet	16812000	6792048
34	Amitriptyline Tablet 75 mg	Tab. Amitryptillin hydrochloride 75 mg. FC, Strip of 10 Tablets	Tablet	278910	557820
35	Amlodipine Tab. 10 mg	Tab Amlodipine besylate 10 mg Aluminium Blister - Strip of 10 Tablets	Tablet	54876825	71559380
36	Amlodipine Tab. 2.5mg	Tab Amlodipinebesylate 2.5 mg Aluminium Blister - Strip of 10 Tablets	Tablet	78136976	6250958
37	Amlodipine Tab. 5 mg	Tab Amlodipine besylate 5 mg Aluminium Blister - Strip of 10 Tablets	Tablet	957650101	111087412
38	Amoxicillin 125 mg Dispersable Kid Tablets Tab	Amoxicillin 125 mg Dispersable Kid Tablets Tab	Tablet	11250	5220
39	Amoxicillin (875mg) + Clavulanic acid(125mg)Tablet	Tab. Amoxycillin I P 875 mg + Clavulanic acid I P 125 mg - Strip of 6 Tablets	Tablet	1520100	8998992
40	Amoxicillin Capsule 250 mg	Amoxicillin Capsule 250 mg	Capsule	54000891	36055315
41	Amoxicillin Tablet 500 mg	Each Amoxycillin Tablet 500 mg contains; Amoxycillin Tryhydrate 500 mg, Strip of 10 Tablet	Tablet	454477500	1127104200
42	Amoxycillin + Clavulanic Acid + Lactic Acid Bacillus 625mg Tab	Each Film Coated Tab/Cap to contain Amoxycillin Trihydrate IP Equivalent to Amoxycillin 500mg, Pottasium Clavulanate Diluted IP Equivalent to Clavulanic Acid 125mg, Lactic Acid Bacillus60 million spores, Excipients q.s.	Tablet	59625	769401
43	Amoxycillin + Clavulanic acid Tab. (500mg+125mg)	Amoxycillin + Clavulanic acid Tab. (500mg+125mg), Each contains Tab. Amoxycillin I P 500 mg + Clavulanic acid I P 125 mg, Strip of 6 Tablets	Tablet	277431343	1252458248
44	Amoxycillin + Clavulanic acid Tab.(250mg+125mg)	Amoxycilln 250 mg + Clavulanic acid 125mg Tab	Tablet	56700	192326

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
45	Amoxycillin Tab. DT 250 mg	Tab. Amoxycillin D T 250 mg contains Dispersible Amoxycillin 250 mg., Strip of 10 Tablet	Tablet	78122700	160745268
46	Amoxycillin Trihydrate 500 mg Cap	Amoxycillin Trihydrate 500 mg Cap	Capsule	756000	2848850
47	Ampicillin Capsule 500 mg	Capsule Ampicillin 500 mg., Each capsule contains Ampicillin 500 mg, Alluminium Blister pack of 10 Capsule	Capsule	27209520	41358470
48	Anti Oxidant Cap	Each Tab/cap to contain: Methylcobalamin 500mcg, Folic Acid IP 1.5mg, Zinc Sulphate IP 25mg, Chromium Polynicotinate 200mcg, Selenium 65mcg as Sodium Selenite USP Pyridoxine Hcl IP 1.5mg, Inositol 100mg, Alpha Lipoic Acid USP 50mg Each Inner capsule contains: Streptococcus Faecalis T-110 JPC 30 million Clostridium Butyricum T-OA 2 million Bacillus Mesentericus T-OA JPC 1 million Lactic Acid Bacillus 50 million (Lactobacillus Sporogenes)	Capsule	337500	4563000
49	Aripiprazole 5mg Tablet	Aripiprazole 5mg Tablet	Tablet	247500	106920
50	Artemether 20mg & Lumefantrine 120mg Tab	Each Tab/Cap to contain: Artemether 20mg & Lumefantrine 120mg	Tablet	45000	111600
51	Artemether 80mg + Lumefantrine 480mg plain/ Dispersible Tab/Cap	Each Plain/ Dispersible Tab/Cap contain:Artemether 80mg + Lumefantrine 480mg	Capsule	1125	6921
52	Artesunate Tab 200mg	Artesunate 200 mg Tab	Tablet	1125	10260
53	Artesunate Tab 50mg	Artesunate 50 mg Tab	Tablet	3488	6138
54	Ascorbic acid (Vitamin C) 100mg	Tab. Ascorbic acid 100 mg., Each Tablet contains; Ascorbic Acid (Vitamin C) 100 mg, Strip of 10 Tablets	Tablet	27918000	4466880
55	Ascorbic acid (Vitamin C) 500mg	Tab. Ascorbic acid 500 mg., Each Tablet contains; Ascorbic Acid (Vitamin C) 500 mg, Strip of 10 Tablets	Tablet	99701550	64937614
56	Aspirin 75 mg Enteric Coated Tab	Aspirin 75 mg Enteric Coated Tab	Tablet	1932750	850410

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
57	Atenolol Tablet 100mg	Tab. Atenolol 100 mg Aluminium Blister - Strip of 14 Tablets	Tablet	89100	22810
58	Atenolol Tablet 50mg	Tab. Atenolol 50 mg Aluminium Blister - Strip of 14 Tablets	Tablet	169411905	29816495
59	Atorvastatin + Methylcobalamine Tablet	"Each Tab/Cap to contain: Atorvastatin Calcium IP Equivalent to Atorvastatin 10mg, Methylcobalamin 500 mcg, Folic Acid IP 5mg , Pyridoxine Hcl IP 10mg"	Tablet	180000	1572480
60	Atorvastatin Tab 20 mg	Atorvastatin 20 mg Tab	Tablet	8023500	3081024
61	Atorvastatin Tablet 10 mg	Tab. Atorvastatin 10 mg, Each Tablet contains Atrovastatin 10 mg, Strip of 10 Tablets	Tablet	58848750	13888305
62	Atorvastatin Tablet 40mg	Tab. Atorvastatin 40 mg, Each Tablet contains Atrovastatin 40 mg, Strip of 10 Tablets	Tablet	16875000	9720000
63	Azathioprine 50mg Tab	Azathioprine 50mg Tab	Tablet	143829	247961
64	Azithromycin DT Tab 100 mg Tab	Azithromycin DT Tab 100 mg Tab	Tablet	11475	27540
65	Azithromycin Tab. 250mg	Tab. Azithromycin 250 mg- Aluminium Blister - Strip of 3 Tab	Tablet	57359813	342029679
66	Azithromycin Tab. 500mg	Tab. Azithromycin 500 mgAluminium Blister - Strip of 3 Tab	Tablet	160458750	103656352 5
67	Baclofen 20 mg Tablet	Tablet Baclofen 20 mg	Tablet	3488	5580
68	Betahistine 8mg Tablet	Betahistine 8mg Tablet	Tablet	298125	243270
69	Bicalutamide Tablet 50mg	Biculatamide 50 mg Tablet; Each contains Biculatamide 50 mg, Strip of 10 Tablets	Tablet	1373	6588
70	Bisacodyl Tab. 5mg	Bisacodyl Tab. 5mg, Strip of 10 Tablets	Tablet	29001600	11484634
71	Bromelain 90mg + Trypsin 48mg + Rutoside 100mg Tab	Bromelain 90mg + Trypsin 48mg + Rutoside 100mg Tab	Tablet	75600	1330560
72	Buprenorphine Tablet 0.4mg	Buprenorphine Tablet 0.4mg; Each contains Buprenorphine 0.4mg	Tablet	8910	14256

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
73	Cabergoline 0.5mg Tab	Cabergoline 0.5mg Tab	Tablet	19350	1136232
74	Calcium Carbonate Tab + Vit D3	Tab Calcium Carbonate-1.25 gm, i.e.1250 mg Vit D3-250 iu, Strip of 15 Tablets	Tablet	119776500	27906219
75	Calcium Carbonate Tablet 250mg	Calcium Carbonate Tablet 250mg, Strip of 15 Tablets	Tablet	27013365	33280466
76	Calcium Carbonate Tablet 500mg	Calcium Carbonate Tablet 500mg, Strip of 15 Tablets	Tablet	187165337	259036826
77	Calcium Citrate 1000mg, Methylcobalmin 500mcg Tab/Cap	Calcium Citrate 1000mg, Vit. D3 200 IU, Methylcobalmin 500mcg, Folic Acid 5mg, Pyridoxin IP 10mg Tab/Cap- Each Tab/Cap to contain: Calcium citrate 1000 mg, Vit. D3 200 IU, Methylcobalmin 500 mcg, Folic acid 5 mg, Pyridoxin IP 10mg	Capsule	225000	1555200
78	Calcium Folate Tablet 15mg.	Calcium Folate Tab 15mg. Contains; Calcium Folate 15mg in Each, Strip of 10 Tablets	Tablet	8910	29938
79	Cap. Danazol 50 mg	Danazol 50 mg Cap	Capsule	1000	2000
80	Cap. Etoposide 100 mg	Cap. Etoposide 100 mg, Strip of 4 Capsule	Capsule	1125	18000
81	Cap. Etoposide 50 mg	Cap. Etoposide 50 mg, Strip of 4 Capsule	Capsule	1170	14040
82	Cap. Hydroxy Urea 500	Hydroxyurea 500 mg Cap	Capsule	833625	2040714
83	Capreomycin 500 mg	Capreomycin 500 mg	Capsule	1000	106400
84	Capsule Tacrolimus 0.5mg	Capsule Tacrolimus 0.5mg	Capsule	3533	282600
85	Capsule Tacrolimus 1mg	Capsule Tacrolimus 1mg	Capsule	10800	216000
86	Carbamazepine CR Tablet 200mg	Tab. Carbamazepine 200 mg CR contains Carbamazepine Controlled Release 100 mg, Strip of 10 Tablets	Tablet	278910	200815
87	Carbamazepine CR Tablet 400mg	Tab. Carbamazepine 400 mg CR contains Carbamazepine Controlled Release 100 mg, Strip of 10 Tablets	Tablet	278910	223128

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
88	Carbamazepine Tablet 200 mg	Carbamazepine Tablet 200 mg	Tablet	11725832	11237100
89	Carbamezapine Tab 100mg	Tab. Carbamezapine 100 mg contains Carbamezapine 100 mg, Strip of 10 Tablets	Tablet	3532950	3320973
90	Carbimazole Tab 5 mg	Tab Carbimazole 5 mg, contains Carbimazole 5 mg, Strip of 10 Tablets	Tablet	109620	50425
91	Carbimazole Tablet 10 mg	Tab Carbimazole 10 mg, contains Carbimazole 10 mg, Strip of 10 Tablets	Tablet	8910	4990
92	Carvedilol 6.25 mg tablet	Tablet Carvedilol 6.25 mg	Tablet	1125	630
93	Cefadroxil 100 mg Tablet	Cefadroxil 100 mg Tablet contains; Cefadroxil Monohydrate IP equivalent to Anhydrous Cefadroxil 100 mg, Strip of 10 Tablets	Tablet	27138510	32566212
94	Cefadroxil 500 mg Tablet	Cefadroxil 500 mg Tablet contains; Cefadroxil Monohydrate IP equivalent to Anhydrous Cefadroxil 500 mg, Strip of 10 Tablets	Tablet	5408910	18606650
95	Cefixime + Pre & Probiotic Capsule	Each Tab/cap. to contain: Cefixime IP as Trihydrate equivalent to Anhydrous Cefixime 200 mg and Each Inner cap to contain: Sterptococcus Faecalis T-110 JPC 60million Clostridium Butyricum TO-A 4 million Bacillus MesentericusTO-AJPC 2 million Lactic Acid Bacillus 100million	Capsule	168750	2061450
96	Cefixime Tab 200mg	Cefixime Tab 200 mg, Strip of 10 Tablets	Tablet	93126645	291541530
97	Cefixime Tab 400 mg	Cefixime Tab 400 mg, Strip of 10 Tablets	Tablet	789750	4422600
98	Cefpodoxime proxetil Tab 100 mg	Cefpodoxime proxetil 100mg Tab	Tablet	11475	21848
99	Cefuroxime 250 mg Tablet	Cefuroxime 250 mg Each Tablet contains; Cefuroxime 250 mg, Strip of 10 Tablets	Tablet	3341385	5613527
100	Cetirizine Hydrochloride Tab 10mg	Tab. Cetirizine Di-Hydrochloride 10 mg Aluminium Blister - Strip of 10 Tablets	Tablet	585033750	92201319

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
101	Cetirizine Hydrochloride Tab 5mg	Tab. Cetirizine Di Hydrochloride 5 mg Aluminium Blister - Strip of 10 Tablets	Tablet	343989450	57790228
102	Chlorambucil Tab 2mg	Tab Chlorambucil 2 mg, Strip of 10 Tablets	Tablet	1000	32400
103	Chlordiazepoxide 10 mg	Chlordiazepoxide 10 mg	Tablet	11250	25560
104	Chloroquine 250 mg Tab	Chloroquine 250 mg Tab	Tablet	3150	2117
105	Chloroquine Tab 150mg	Chloroquine Tab 150mg	Tablet	1213110	1183995
106	Chlorpheniramine 4 mg Tab	Chlorpheniramine 4 mg Tab	Tablet	168750	121500
107	Chlorpheniramine Maleate Tab 4mg	Tab. Chlorpheniramine maleate 4 mg Aluminium Blister - Strip of 10 Tablets	Tablet	368409600	70734643
108	Chlorpheniramine Tablet 10 mg	Chlorpheniramine Tablet 10 mg	Tablet	8910	620
109	Chlorpheniramine Tablet 20 mg	Chlorpheniramine Tablet 20 mg	Tablet	8910	7841
110	Chlorpheniramine Tablet 40 mg	Chlorpheniramine Tablet 40 mg	Tablet	8910	16394
111	Chlorpheniramine Tablet 5 mg	Chlorpheniramine Tablet 5 mg	Tablet	4455000	285120
112	Chlorpromazine Tab 25 mg	Chlorpromazine 25mg Tab	Tablet	2250	540
113	Chlorpromazine Tablet 100 mg	Tab. Chlorpromazine Hydrochloride 100 mg	Tablet	8910	5560
114	Chlorpromazine Tablet 50mg	Chlorpromazine 50 mg Tab	Tablet	1000	440
115	Cholecalciferol 1000 IU Tablet	Cholecalciferol 1000 IU Tablet	Tablet	4953726	8441149
116	Cholecalciferol 60000 IU Cap	Each Cap/Tab to contain : Vit. D3 60,000 IU	Capsule	198000	419760
117	Cholecalciferol Tablet 60000 IU	Vitamin D3 (Cholecalciferol) 60,000 IU/g Tablet	Tablet	62694000	175543200
118	Cholecalciferol USP 125 mg Tablet	Cholecalciferol USP 125 mg Tablet	Tablet	133380	373464

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
119	Ciprofloxacin Tab. 250mg	Tab. Ciprofloxacin 250 mg, Strip of 10 Tablets	Tablet	34292250	27296631
120	Ciprofloxacin Tab. 500mg	Tab. Ciprofloxacin 500 mg, Strip of 10 Tablets	Tablet	125407350	151411818
121	Clindamycin Cap 150 mg	Clindamycin 150 mg Cap	Capsule	11250	129240
122	Clindamycin Cap 300mg	Cap. Clindamycin 300 mg, Strip of 5 or 8 Capsules	Capsule	31203	115576
123	Clindamycin Capsule 150 mg (Protect from moisture)	Clindamycin Capsule 150 mg (Protect from moisture)	Capsule	758610	2913062
124	Clobazam Tab 10mg	Tab Clobazam 10 mg, Strip of 10 Tablets	Tablet	30257820	29047507
125	Clobazam Tablet 5 mg	Tab Clobazam 5 mg, Strip of 10 Tablets	Tablet	3672383	3231697
126	Clobazam Tablet 5 mg	Clobazam 10 mg Tab	Tablet	603000	506520
127	Clofazamine Cap 100mg	Tab Clofazimine 100 mg	Capsule	1213223	981740
128	Clofazimine 100 mg Capsule	Capsule Clofazimine 100 mg, Strip of 10 Capsule	Capsule	1213110	2193303
129	Clofazimine 200 mg Capsule	Clofazimine 200 mg Capsule, Strip of 10 Capsule	Capsule	1213110	213507
130	Clofazimine 50 mg Capsule	Capsule Clofazimine 50 mg, Strip of 10 Capsule	Capsule	1213110	2193303
131	Clofibrate Tablet 500mg	Clofibrate Tablet 500mg contains; Clofibrate Magnesium 500 mg, Strip of 10 Tablets	Tablet	8910	27942
132	Clomiphene Citrate Tab 50mg	Tab Clomiphene Citrate 50 mg	Tablet	8910	30650
133	Clonazepam Tab 0.5 mg	Clonazepam Tab 0.5 mg	Tablet	27150795	5973175
134	Clonazepam Tab 2 mg	Clonazepam 2 mg Tab	Tablet	1000	560
135	Clonazepam tablet 0.25 mg	Clonazepam tablet 0.25 mg	Tablet	2256876	234715
136	Clonidine Tablet 100 mcg	Clonidine Tablet 100 mcg	Tablet	33750	54000

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
137	Clopidogrel Tab 75mg	Clopidogrel Tab 75mg	Tablet	24835275	14305118
138	Clotrimazole Tablet 100 mg	Clotrimazole Tablet 100 mg	Tablet	27008910	44921219
139	Cloxacillin Capsule 250 mg	Cloxacillin Capsule 250 mg	Capsule	8910	35640
140	Clozapine 100mg Tablet	Clozapine 100mg Tablet	Tablet	69750	312480
141	Clozapine Tab 100mg	Clozapine Tab 100mg	Tablet	15128910	23722131
142	Clozapine Tab 25mg	Clozapine 25 mg Tab	Tablet	483660	1708287
143	Clozapine Tab 50mg	Clozapine Tab 50mg	Tablet	6249184	5799243
144	Codeine Tablet 15 mg	Codeine Tablet 15 mg	Tablet	8910	21384
145	Colchicine Tablet 0.5mg	Colchicine Tablet 0.5mg	Tablet	26600	19152
146	Cotrimoxazole HS (Trimethoprim 40 mg + Sulphamethoxazole 200mg) for paediatric use Tab	Cotrimoxazole HS (Trimethoprim 40 mg + Sulphamethoxazole 200mg) for paediatric use Tab	Tablet	4725	3024
147	Cyclophosphamide 50mg Tab	Cyclophosphamide 50mg Tab	Tablet	1000	20800
148	Cycloserine Capsule 125mg	Cycloserine Capsule 125mg	Capsule	1213110	46583424
149	Cycloserine Capsule 250mg	Cycloserine Capsule 250mg	Capsule	1213110	46583424
150	Cyclosporin 100 mg Cap	Cyclosporin 100 mg Cap	Capsule	1125	19242
151	Cyclosporine Capsule 50mg	Cyclosporine Capsule 50mg	Capsule	26798	631135
152	Dapsone Tab 100mg	Dapsone Tab 100mg	Tablet	8910	2994
153	Dapsone Tab 25mg	Dapsone Tab 25mg	Tablet	129330	31039

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
154	Deferasirox 400mg Tab	Deferasirox 400mg Tab	Tablet	6750	78462
155	Deferasirox Tab 250mg	Deferasirox 250mg Tab	Tablet	87750	372060
156	Deferasirox Tab 500mg	Deferasirox 500mg Tab	Tablet	355500	2064061
157	Deriphyllin Tablet SR 150 mg	Deriphyllin Tablet SR 150 mg, Strip of 10 Tablets	Tablet	2708910	68936342
158	Dexamethasone 2 mg Tab	Dexamethasone 2 mg Tab	Tablet	1350	648
159	Dexamethasone 4mg Tab	Dexamethasone 4mg Tab	Tablet	4500	5184
160	Dexamethasone Tab. 0.5mg	Tab Dexamethasone 0.5 mg	Tablet	7496624	75565972
161	Dexketoprofen + Paracetamol Tab	Each Tab/Cap to contain: Dexketoprofen 25mg, Paracetamol 325mg	Tablet	112500	621900
162	Diazepam Tab 10 mg	Diazepam Tab 10 mg	Tablet	548910	180042
163	Diazepam Tab 5 mg	Diazepam Tab 5 mg	Tablet	8608995	1790671
164	Diclofenac Sodium Tab. 50mg	Tab. Diclofenac Sodium 50 mg Aluminium Blister - Strip of 10 Tablets	Tablet	105612907 5	142492935
165	Dicyclomine 10 mg Tab	Dicyclomine 10 mg Tab	Tablet	560250	58266
166	Dicyclomine 500 mg Tablet	Dicyclomine 500 mg Tablet	Tablet	5675400	163451520
167	Dicyclomine and Mefenamic Tab	Each Tab/Cap to contain: Dicyclomine 10mg, Mefenamic Acid 250mg	Tablet	147600	112176
168	Dicyclomine Tablet 10 mg (Tablets Protect from light)	Dicyclomine Tablet 10 mg (Tablets Protect from light)	Tablet	221130000	23227495
169	Diethyl Carbamazine 100mg Tab	Diethyl Carbamazine 100mg Tab	Tablet	1238	495
170	Diethylcarbamazine Citrate Tab I.P 100mg	Tab. Diethyl carbamazine 100 mg Aluminium Blister - Strip of 10 Tab	Tablet	8238555	1911345

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
171	Digoxin Tab 0.25 mg	Digoxin 0.25 mg Tab	Tablet	701865	364970
172	Digoxin Tablet 250 mg	Digoxin Tablet 250 mg	Tablet	126900	50760
173	Diloxanide Furoate Tab 500mg	Diloxanide Furoate Tab 500mg	Tablet	8910	2994
174	Diltiazem SR Tab. 90mg	Diltiazem SR Tab. 90mg	Tablet	138240	342835
175	Diltiazem Tab. 30mg	Diltiazem 30 mg Tab	Tablet	15750	7560
176	Diltiazem Tab. 60mg	Diltiazem Tab. 60mg	Tablet	179820	161119
177	Dinoprostone Tab 0.5mg	Dinoprostone Tab 0.5mg	Tablet	8910	213840
178	Diphenylhydantoin 100mg	Diphenylhydantoin 100mg	Tablet	2821311	2008773
179	Disulfiram 250 mg	Disulfiram 250 mg Tablet	Tablet	199238	207207
180	Divalproex sodium Tab 500 mg	Divalproex sodium 500 mg Tab	Tablet	351000	561600
181	Domperidone Mouth Dissolving Tab 10mg	Domperidone 10mg Tab	Tablet	29586870	4265243
182	Donepezil HCL 5 mg Tab	Donepezil HCL 5 mg Tab	Tablet	7700580	5421208
183	Doxycycline Cap / Tab 100mg	Doxycycline Cap / Tab 100mg, Strip of 10 Capsule or Tablets	Capsule	92069775	77706890
184	Duloxetine Tablet 10mg	Duloxetine Tablet 10mg	Tablet	8910	14969
185	Duloxetine Tablet 30mg	Duloxetine Tablet 30mg	Tablet	8910	24948
186	Duloxetine Tablet 60mg	Duloxetine Tablet 60mg	Tablet	8910	34856
187	Dydrogesterone 10 mg Tablet	Dydrogesterone 10 mg Tablet	Tablet	9000	244800
188	Efavirenz Cap 200mg	Efavirenz Cap 200mg	Capsule	8910	99792

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
189	Efavirenz Cap 50mg	Efavirenz Cap 50mg	Capsule	8910	58450
190	Efavirenz Cap 600mg	Efavirenz Cap 600mg	Capsule	8910	85536
191	Enalapril Tab 10 mg	Enalapril Tab 10 mg	Tablet	89100	43481
192	Enalapril Tab 2.5mg	Enalapril 2.5 mg Tab	Tablet	4015800	899539
193	Enalapril Tab 5mg	Enalapril 5 mg Tab	Tablet	7636725	2174939
194	Entecavir 0.5gm(Adult with compensated Liver Disease and Lamivudine Nalve)	Entecavir (Adult with compensated Liver Disease and Lamivudine Nalve) Contains : Entecavir 0.5gm Tablet . Bottle of 30 Tablets	Tablet	1000	4480
195	Entecavir 1 gm(Adult with Decompensated Liver Disease)	Entecavir (Adult with Decompensated Liver Disease) Contains : Entecavir 1gm Tablet . Bottle of 30 Tablets	Tablet	1000	7280
196	Enzyme Tablet containing Trypsin + Chymotrypsine (6:1) equivalent to enzyme activity 1 lac units OR EQUIVALENT	Enzyme Tablet containing Trypsin + Chymotrypsine (6:1) equivalent to enzyme activity 1 lac units OR EQUIVALENT	Tablet	37350	44820
197	Erythromycin Stearate Tab. 250mg	Erythromycin Stearate 250mg Tab	Tablet	13500	17712
198	Erythromycin Stearate Tab. 500mg	Erythromycin Stearate 500mg Tab	Tablet	47250	136080
199	Escitalopram Oxalate 10 mg Tab	Escitalopram Oxalate 10 mg Tab	Tablet	2004750	609444
200	Escitalopram Tab. 10mg	Escitalopram Tab. 10mg	Tablet	23079330	7939290
201	Escitalopram Tablet 5 mg	Escitalopram Tablet 5 mg	Tablet	2782226	623219
202	Ethamsylate 500mg Tab	Each Tab to contain : Ethamsylate 500mg	Tablet	1000	20336
203	Ethamsylate Tab 250 mg	Ethamsylate Tab 250 mg	Tablet	2740950	2170832
204	Ethinylestradiol (A) + Levonorgestrel (B) Tablet 0.03mg(A) +	Ethinylestradiol (A) + Levonorgestrel (B)	Tablet	70011	68891

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
	0.15mg(B) with Ferrous Fumarate	Tablet 0.03mg(A) + 0.15mg(B) with Ferrous Fumarate			
205	Ethinylestradiol tab 0.01 mg	Ethinylestradiol tab 0.01 mg	Tablet	8910	11405
206	Ethinylestradiol tablet 0.05 mg	Ethinylestradiol tablet 0.05 mg	Tablet	8910	14969
207	Etophyllin 231mg + Theophylline 69mg Tab	Etophyllin 231mg + Theophylline 69mg Tab	Tablet	640125	404559
208	Etophylline 77 mg + Theophylline 23 mg Tab	Etophylline 77 mg + Theophylline 23 mg Tab	Tablet	180000	33120
209	Etoricoxib 60mg Tablet	Tablet Etoricoxib 60 mg	Tablet	9000	82800
210	Fenofibrate Tablet 160mg	Fenofibrate Tablet 160mg	Tablet	8910	25661
211	Fenofibrate Tablet 40mg	Fenofibrate Tablet 40mg	Tablet	8910	17107
212	Ferrous Fumarate 200 mg + Cyanocobalamine 15 mcg + Folic Acid 1.5 mg. Sustained release OR EQUIVALENT Cap	Ferrous Fumarate 200 mg + Cyanocobalamine 15 mcg + Folic Acid 1.5 mg. Sustained release OR EQUIVALENT Cap	Capsule	2475000	1528758
213	Ferrous Salt (A)+ Folic acid (B) Tablet 100 mg elemental iron(A) + 500 mcg (B)as enteric coated	Ferrous Salt (A)+ Folic acid (B) Tablet 100 mg Elemental Iron(A) + 500 mcg (B)as enteric coated	Tablet	186273000	19372392
214	Ferrous Salt 100 mg + Folic acid 500 mcg	Feerous Sulphate 333-335 mg (Equivalent to 100 mg of elemental iron) + Folic Acid I P 0.5 mg	Tablet	162089100	18102111
215	Ferrous Salt 20 mg + Folic Acid 100 mcg tablet	Ferrous Salt 20 mg + Folic Acid 100 mcg tablet	Tablet	11855453	6354523
216	Ferrous Salt 45 mg + Folic Acid 100 mcg tablet	Ferrous Salt 45 mg + Folic Acid 100 mcg tablet	Tablet	270008910	26352870
217	Ferrous Salts Equivalent to 60 mg of Elemetal Iron	Ferrous Salts Equivalent to 60 mg of Elemetal Iron	Tablet	1711946	1040863
218	Ferrous Sulphate 200 mg Tab	Ferrous Sulphate 200 mg Tab	Tablet	112500	24300

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
219	Fexofenadine 120 mg Tab	Fexofenadine 120 mg Tab	Tablet	2250	2700
220	Flucanazole Tab 100 mg	Fluconazole 100mg Tab	Tablet	11250	11700
221	Flucanazole Tab 200 mg	Fluconazole 200mg Tab	Tablet	11250	27000
222	Fluconazole Tab. 150 mg	Fluconazole Tab. 150 mg	Tablet	49831830	61273218
223	Flunarizine Tab 10 mg	Flunarizine Tab 10 mg	Tablet	8910	13472
224	Flunarizine Tab 5mg	Flunarizine Tab 5mg	Tablet	8910	8554
225	Fluoxetine Cap 20mg.	Fluoxetine Capsule 20mg., Strip of 10 Capsules	Capsule	15729120	8174109
226	Fluoxetine 20mg Tab	Fluoxetine 20mg Tab	Tablet	1224000	518976
227	Folic acid Tab 400 mcg	Tab. Folic Acid 400 mcg (0.4 mg) Strip of 10 Tablets	Tablet	108008910	17281426
228	Folic acid Tab 5mg	Tab Folic Acid 5 mg. Strip of 10 Tablets	Tablet	1015365150	174642806
229	Formaline 1 gm Tab	Formaline 1 gm Tab	Tablet	74363	47592
230	Furosemide Tab. 40mg	Furosemide 40mg Tab	Tablet	1722375	551160
231	Furosemide Tab. 40mg	Tab. Furosemide 40 mg Aluminium Blister - Strip of 10 Tab	Tablet	5235701	2345594
232	Gabapentin Tablet 100mg	Gabapentin Tablet 100mg	Tablet	8910	18533
233	Gabapentin Tablet 300mg	Tablet Gabapentin 300 mg	Tablet	127125	722070
234	Gabapentin Tablet 400mg	Gabapentin Tablet 400mg	Tablet	8910	29225
235	Glibenclamide 5mg + Metformin 500mg	Tab Glibenclamide 5mg + Metformin 500mg, Strip of 10 Tablets	Tablet	18333000	19066320
236	Glibenclamide Tab 2.5mg	Glibenclamide Tab 2.5mg	Tablet	5072918	1095750

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
237	Glibenclamide Tab 5mg	Glibenclamide Tab 5mg	Tablet	6291000	1912464
238	Glibenclamide Tab 5mg	Glibenclamide 5mg Tab	Tablet	292500	48672
239	Glicazide Tab 80 mg	Gliclazide 80mg Tab	Tablet	303750	393660
240	Gliclazide 60 mg Tab	Gliclazide 60 mg Tab	Tablet	112500	268200
241	Gliclazide 80 mg + Metformin 500 mg Extended release Tab	Gliclazide 80 mg + Metformin 500 mg Extended release Tab	Tablet	315000	408240
242	Glimiperide 1mg Tab	Glimiperide 1mg Tab	Tablet	416985300	53374118
243	Glimiperide 2mg Tab	Glimiperide 2mg Tab	Tablet	222540750	30265542
244	Glimiperide 2mg Tab	Glimepiride 2 mg Tab	Tablet	2250000	342000
245	Griseofulvin 250 mg Tab	Griseofulvin 250 mg Tab	Tablet	137250	237168
246	Griseofulvin Tablet 125 mg	Griseofulvin Tablet 125 mg	Tablet	6371910	5250454
247	Griseofulvin Tablet 250 mg	Griseofulvin Tablet 250 mg	Tablet	8910	9266
248	Haloperidol Tab 1.5 mg	Haloperidol 1.5 mg Tab	Tablet	67500	13500
249	Haloperidol Tab 5mg	Tab. Haloperidol 5 mg	Tablet	17379720	15016078
250	Haloperidol Tablet 1.5 mg	Haloperidol Tablet 1.5 mg	Tablet	8910	1025
251	Hydrochlorothiazide Tablet 12.5 mg	Hydrochlorothiazide 12.5 mg Tablet	Tablet	2034900	463957
252	Hydrochlorothiazide Tablet 25 mg	Hydrochlorothiazide Tablet 25 mg	Tablet	1926965	863280
253	Hydrochlorothiazide Tablet 50mg	Hydrochlorothiazide Tablet 50mg	Tablet	178200	142560
254	Hydroxy Chloroquine Tab 150mg	Hydroxy Chloroquine Tab 150mg	Tablet	109316	174906

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
255	Hydroxy Urea Tab 500mg	Hydroxy Urea Tab 500mg, Strip of 10 Tablets	Tablet	3239730	336931920
256	Hydroxychloroquine sulphate 200mg Tab	Hydroxychloroquine sulphate 200mg Tab	Tablet	227250	447228
257	Hydroxychloroquine Tab 200mg	Hydroxychloroquine Tab 200mg	Tablet	404730	25546558
258	Hydroxychloroquine Tablet 400mg	Hydroxychloroquine Tablet 400mg	Tablet	8910	1218888
259	Hydroxyzine HCL 25mg Tab	Hydroxyzine HCL 25mg Tab	Tablet	1348110	14818425
260	Hyoscine Butyl bromide 10mg Tab	Each Tab/ Cap to contain: Hyoscine Butylbromide 10mg	Tablet	4500	5796
261	Hyoscine Butyl Bromide Tablet 10 mg	Hyoscine Butyl Bromide Tablet 10 mg	Tablet	8910	240926
262	Hyoscine Butyl-Bromide Tablet 500 mg	Hyoscine Butyl-Bromide Tablet 500mg	Tablet	98010	1332936
263	Ibuprofen Tab. 200mg	Ibuprofen 200mg Tab	Tablet	27918000	8263728
264	Ibuprofen Tab. 400mg	Ibuprofen 400 mg Tab	Tablet	183133125	90834030
265	Imatinib Tab 100mg	Imatinib Tab 100mg	Tablet	8910	4893586
266	Imatinib Tab 400mg	Imatinib Tab 400mg	Tablet	19710	13246066
267	Imipramine HCL 25 mg Tab	Imipramine HCL 25 mg Tab	Tablet	15834330	12414115
268	Imipramine tablet 75 mg	Imipramine tablet 75 mg	Tablet	8910	10336
269	Indapamide Tablet 1.5 mg	Indapamide Tablet 1.5 mg	Tablet	44550	53460
270	Iron & Folic Acid (elemental iron 60mg + Folic Acid 0.5mg) Tab	Iron & Folic Acid(elemental iron 60mg+Folic Acid 0.5mg) Tab	Tablet	451010160	69112797
271	Iron + folic acid Tab (Ferrous sulphate 333-335 mg (Equivalent to 100 mg of elemental iron) + Folic Acid I P 0.5 mg Tab	Iron + folic acid Tab (Ferrous sulphate 333-335 mg (Equivalent to 100 mg of elemental iron) + Folic Acid I P 0.5 mg Tab	Tablet	9247500	1056434

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
272	Iron + folic acid Tab (Ferrous sulphate I P equivalent to 30 mg of elemental iron + Folic Acid 250 mcg Tab	Iron + folic acid Tab {Ferrous sulphate I P equivalent to 30 mg of elemental iron + Folic Acid 250 mcg Tab	Tablet	4500	3240
273	Iron And Vitamin Tab	Each Tab/Cap to contain: Ferrous Fumarate 350 mg, Vit. C 150 mg, Vit B12 - 15 mcg, Folic Acid 1.5 mg.	Tablet	182250	558414
274	Isoniazide 50mg + Rifampicin 75mg	2FDC (Pediatric)-CP Isoniazide 50mg + Rifampicin 75mg	Tablet	1204200	1734048
275	Isoniazide 50mg + Rifampicin 75mg + Pyrazinamide 150mg	3FDC (Pediatric)-IP Isoniazide 50mg + Rifampicin 75mg + Pyrazinamide 150mg	Tablet	1204200	5105808
276	Isoniazide 75mg + Rifampicin 150mg + Ethambutol 275mg	3FDC (Adult)-CP Isoniazide 75mg + Rifampicin 150mg + Ethambutol 275mg	Tablet	1204200	2215728
277	Isoniazide 75mg + Rifampicin 150mg +Pyrazinamide 400mg + Ethambutol 275mg	4FDC (Adult)-IP Isoniazide 75mg + Rifampicin 150mg +Pyrazinamide 400mg + Ethambutol 275mg	Tablet	1204200	6261840
278	Isosorbide Dinitrate Tab 10mg	Isosorbide Dinitrite 10 mg Tab	Tablet	3797550	1822824
279	Isosorbide Dinitrate Tab 5mg	Isosorbide dinitrate 5 mg Tab	Tablet	3736260	1629009
280	Isosorbide Mono Nitrate SR Tab 30mg	Tab. Isosorbide Mononitrate Sustained Release 30 mg Aluminium Blister - Strip of 10 Tablets	Tablet	89100	71280
281	Isosorbide Mono Nitrate Tab 10mg	Tab. Isosorbide Mononitrate 10 mg Aluminium Blister - Strip of 10 Tablets	Tablet	105300	92664
282	Isosorbide Mono Nitrate Tab 5mg	Tab. Isosorbide Mononitrate 5 mg Aluminium Blister - Strip of 10 Tablets	Tablet	1247135	1995415
283	Isoxsuprine Tab 10mg	Isoxsuprine 10 mg Tab	Tablet	51750	27324
284	Itraconazole 100 mg Capsule	Itraconazole 100 mg Cap	Capsule	58547250	213111990
285	Ivermectin Tablet 600 mg	Ivermectin Tablet 600 mg	Tablet	8910	7128
286	Ivermectine Tab 6mg	Tab Ivermectin 6 mg. One Single Tablet Pack	Tablet	1039311	69841699
287	Ketorolac tromethamine Dispersible 10mg Tablet	Ketorolac tromethamine Dispersible 10mg Tablet	Tablet	17640	7770349

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
288	Labetalol Tab 100mg	Labetalol HCl 100 mg Tab	Tablet	5010638	250291364
289	Lamivudine 150mg + Zidovudine 300mg Tab.	Tab. Lamivudine 150 mg + Zidovudine 300 mg, Strip of 10 tablets	Tablet	8910	69926
290	Levetiracetam Tab 250mg	Levetiracetam 250mg Tab	Tablet	22966830	613489963
291	Levetiracetam tab. 500 mg	Levetiracetam 500mg Tab	Tablet	17389080	845290134
292	Levodopa (A) + Carbidopa (B) CR Tablet 100 mg (A) + 25mg(B)	Levodopa (A) + Carbidopa (B) CR Tablet 100 mg (A) + 25mg(B)	Tablet	8910	14969
293	Levodopa (A) + Carbidopa (B) CR Tablet 200 mg (A) + 50mg(B)	Levodopa (A) + Carbidopa (B) CR Tablet 200 mg (A) + 50mg(B)	Tablet	8910	22810
294	Levodopa 100mg + Carbidopa 10mg Tab	Levodopa 100mg + Carbidopa 10mg Tab	Tablet	8910	641520
295	Levodopa 100mg + Carbidopa 25mg Tab	Levodopa 100mg + Carbidopa 25mg Tab	Tablet	8910	12910
296	Levodopa 200mg + Carbidopa 50mg Tab	Levodopa 200mg + Carbidopa 50mg Tab	Tablet	8910	27799
297	Levodopa 250mg + Carbidopa 25mg Tab	Levodopa 250mg + Carbidopa 25mg Tab	Tablet	8910	29938
298	Levofloxacin 250 mg Tablet	Levofloxacin 250mg Tablet	Tablet	1000	1600
299	Levonorgestrel 1.5 mg Tablet	Tablet Levonorgestrel 1.5 mg, Strip of 10 tablets	Tablet	189540	909792
300	Levosalbutamol 1.25mg + Ipratropium 500mcg Respules 3ml	Levosalbutamol 1.25mg + Ipratropium 500mcg Respules 3ml	Tablet	472950	2160436
301	Levosalbutamol 50 mcg	Levosalbutamol 50 mcg Single Dose Inhaler	Tablet	1000	44840
302	Levothyroxine Tablet 100 mcg (Protect from light and moisture)	Levothyroxine Tablet 100 mcg (Protect from light and moisture)	Tablet	8910	2581
303	Levothyroxine Tablet 25 mcg	Levothyroxine Tablet 25 mcg contains; Levothyroxine Sodium 25 mcg	Tablet	8910	1653696

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
304	Levothyroxine tablet 50 mcg	Levothyroxine Tablet 50 mcg contains; Levothyroxine Sodium 50 mcg	Tablet	8910	5346
305	Linezolid Tablet 600mg.	Linezolid 600 mg Tab	Tablet	1502064	9216665
306	Lisinopril Tab 5mg	Lisinopril 5 mg Tab	Tablet	13410	9816
307	Lithium Carbonate Tab 300 mg.	Lithium Carbonate 300 mg Tab	Tablet	8196435	27277736
308	Liver Disorders Tab	Each Tab/Cap to contain: DL-Methionine BP 200mg , Choline Bitartrate (as coated) USP 200mg, L-Leucine USP 19mg, L-Isoleucine USP 10mg, L-Valine USP 11mg, Pyridoxine Hydrochloride IP 1.5mg, Nicotinamide IP 22.5mg, Biotin USP 0.1mg, Folic Acid IP 0.5 mg, Cyanocobalamin IP 3.0 mcg, Inositol BP 50 mg	Tablet	11250	53820
309	Loperamide Tab 2mg	Loperamide Tab 2mg	Tablet	9077400	5809536
310	Lopinavir 133 mg + Ritonavir cap 33mg	Lopinavir 133mg + Ritonavir 33mg Capsule	Capsule	8910	166296
311	Lopinavir 200mg + Ritonavir 50mg Tablet	Lopinavir 200mg + Ritonavir 50mg Tablet	Tablet	8910	434808
312	Lorazepam 2mg Tablet	Lorazepam 2mg Tablet, Strip of 10 Tablets	Tablet	16873110	8639032
313	Lorazepam Tab 1mg	Lorazepam Tab 1mg	Tablet	3121133	2247215
314	Lorazepam Tab 2mg	Lorazepam 2 mg Tab	Tablet	2013413	547648
315	Losartan Potassium Tab 50mg	Losartan potassium 50 mg Tab	Tablet	37125	19008
316	Medroxy Progesterone Tab 10mg	Medroxy Progesterone Tab 10mg	Tablet	8910	13543
317	Mefenamic Acid 250mg Capsule	Cap. Mefenamic Acid 250mg, Strip of 10 Capsule	Capsule	2717820	31896336
318	Mefenamic Acid 500mg Capsule	Cap. Mefenamic Acid 500mg, Strip of 10 Capsule	Capsule	3032910	9705312

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
319	Mefloquine Tab 250mg	Mefloquine 250 mg Tab	Tablet	1000	21712
320	Metformin Controlled Released 750 mg	Metformin Controlled Released 750 mg Tablet, Strip of 10 Tablets	Tablet	2875185	1564101
321	Metformin SR Tab 500mg	Metformin SR Tab 500mg, Strip of 10 Tablets	Tablet	3564000	1938816
322	Metformin Tab 500mg	Metformin 500mg Tab	Tablet	1003443559	1084200696
323	Methadone Tab 40mg	Methadone Tab 40mg	Tablet	8910	63368
324	Methadone Tab 5mg	Methadone Tab 5mg	Tablet	8910	37066
325	Methotrexate Tab 5 mg	Methotrexate 5 mg Tab	Tablet	11475	64627
326	Methyl Dopa Tab 250 mg	Methyl Dopa 250 mg Tab	Tablet	1125	1134
327	Methyl Ergometrin Tab 0.125mg	Methyl Ergometrin Tab 0.125mg	Tablet	586710	2018282
328	Methyl prednisolone Tab 4mg	Methyl prednisolone 4 mg Tab	Tablet	551160	983269
329	Methyl prednisolone Tablet 32mg	Methylprednisolone Tablet 32mg	Tablet	8910	1348390
330	Methylcobalamin 1500mcg Tablet	Methylcobalamin 1500mcg Tablet	Tablet	123750	100980
331	Methylergometrine maleate 0.125 mg Tab	Methylergometrine maleate 0.125 mg Tab	Tablet	11475	18819
332	Methylprednisolone sodium succinate 125mg	Methylprednisolone sodium succinate 125mg	Tablet	1000	48280
333	Methylprednisolone Tablet 8mg	Methylprednisolone Tablet 8mg	Tablet	8910	1429100
334	Metoclopramide Tab 10mg	Metoclopramide Tab 10mg	Tablet	5529330	1990559
335	Metolazone 5mg Tablet	Metolazone 5mg Tablet	Tablet	2250	16200
336	Metoprolol SR Tab 25mg	Each Tab/Cap to contain : S(-)Metoprolol Succinate 23.75 mg Eqv. to S(-) Metoprolol Tartrate 25 mg	Tablet	847035	3150970

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
337	Metoprolol SR Tab 50mg	Metoprolol SR Tab 50mg	Tablet	1358910	2935246
338	Metoprolol Tab 100mg	Metoprolol Tab 100mg	Tablet	89100	40630
339	Metoprolol Tab 25mg	Metoprolol 25 mg Tab	Tablet	5522850	1877769
340	Metoprolol Tab 50mg	Metoprolol 50 mg Tab	Tablet	5882535	4211895
341	Metronidazole Tab 200mg	Metronidazole 200mg Tab	Tablet	35297325	14824877
342	Metronidazole Tab 400mg	Metronidazole 400mg Tab	Tablet	202384800	156524404
343	Miconazole Vaginal Tablet 200 mg	Miconazole Vaginal Tablet 200 mg	Tablet	8910	43669
344	Micronised Purified flavonoid fraction 500mg Tab	Micronised Purified flavonoid fraction 500mg Tab	Tablet	180000	1474560
345	Midazolam Tablet 250 mg	Midazolam Tablet 250 mg	Tablet	8910	3564
346	Midazolam Tablet 500 mg	Midazolam Tablet 500 mg	Tablet	1000	800
347	Mifepristone Tab 200 mg	Mifepristone 200mg Tab	Tablet	13298	126592
348	Mifepristone+Misoprostol (1 Tablet of Mifepristone 200 mg and 4 Tablets of Misoprostol 200 mcg)	Mifepristone+misoprostol (1 tablet of mifepristone 200 mg and 4 tablets of misoprostol 200 mcg)	Tablet	86346	414461
349	Miltefosine Capsule 10 mg	Miltefosine Capsule 10 mg	Capsule	8910	2851200
350	Miltefosine Capsule 50mg	Miltefosine Capsule 50mg	Capsule	8910	7128
351	Misoprostol Tab 100mcg	Misoprostol Tab 100mcg	Tablet	89100	558835
352	Misoprostol Tab 200mcg	Misoprostol 200mcg Tab	Tablet	1658790	7418109
353	Misoprostol Tab 25 mcg	Misoprostol 25mcg Tab	Tablet	4613	5203

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
354	Monteleukast 10mg and levocetirizine 5mg Tablet	Monteleukast 10mg and levocetirizine 5mg Tablet	Tablet	493875	251363
355	Montelukast 10mg and Bilastine 20mg Tablet	Montelukast 10mg and Bilastine 20mg Tablet	Tablet	56250	66150
356	Morphine Tab 20mg	Morphine Tab 20mg	Tablet	2239	269
357	Morphine Tab SR/30mg	Morphine Tab SR/30mg	Tablet	1000	3880
358	Morphine Tablet 10 mg	Morphine Tablet 10 mg	Tablet	8910	314202
359	Multivitamin Tab/Cap	Multivitamin Tab/Cap	Capsule	9558000	12693024
360	Mycophenolate Mofetil Tab 250mg	Mycophenolate Mofetil Tab 250mg	Tablet	14198	11358
361	N-Acetyl Cystine Tablet 600mg	N-Acetyl Cystine Tablet 600mg	Tablet	129330	6186113
362	Naproxen 250 mg Tab	Naproxen 250 mg Tab	Tablet	4500	6336
363	Naproxen Tablet 250 mg	Naproxen Tablet 250 mg	Tablet	675810	1135361
364	Naproxen Tablet 500 mg	Naproxen Tablet 500 mg	Tablet	1933200	4485024
365	Nevirapine Dispersible tablet 200mg	Nevirapine Dispersible Tablet 200mg	Tablet	8910	163944
366	Nevirapine Dispersible Tablet 50mg	Nevirapine Dispersible Tablet 50mg	Tablet	8910	67003
367	Nicorandil Tab 5mg	Nicorandil 5 mg Tab	Tablet	11250	17100
368	Nicotinamide Tab 50mg	Nicotinamide Tab 50mg	Tablet	1148108	468428
369	Nicotine 2 mg (for nicotine replacement therapy)	Nicotine 2 mg (for nicotine replacement therapy) Chewable Tablet	Tablet	8910	14256
370	Nicotine 4 mg (for nicotine replacement therapy)	Nicotine 4 mg (for nicotine replacement therapy) Chewable Tablet	Tablet	8910	28512
371	Nifedipine 10 mg Tab	Nifedipine 10 mg Tab	Tablet	1777455	782080

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
372	Nifedipine 5 mg Cap	Nifedipine 5 mg Cap	Capsule	53775	13336
373	Nifedipine Cap (Liquid) 10mg	Nifedipine Cap (Liquid) 10mg	Capsule	1875429	2175498
374	Nifedipine Cap (Liquid) 5mg	Nifedipine Cap (Liquid) 5mg	Capsule	4014227	4495935
375	Nifedipine Retard 20mg Tab	Nifedipine Retard 20mg Tab	Tablet	137250	258030
376	Nitrazepam Tab 5 mg	Nitrazepam 5 mg Tab	Tablet	11250	4050
377	Nitrofurantoin 100 mg tablet	Tablet Nitrofurantoin 100 mg	Tablet	96075	122976
378	Nitrofurantoin Tab 50mg	Nitrofurantoin 50 mg Tab	Tablet	7875	5859
379	Nitrofurantoin Tablet 100 mg	Nitrofurantoin Tablet 100 mg	Tablet	9990	9208
380	Norethisterone Tab 5mg	Norethisterone 5mg Tab	Tablet	900180	630126
381	Norfloxacin 400mg and Tinidazole 600mg Tablet	Norfloxacin 400mg and Tinidazole 600mg Tablet	Tablet	45000	120240
382	Norfloxacin Dispersible Tablet 100 mg	Tab. Norfloxacin Dispersible 100 mg Aluminium Blister - Strip of 10 Tab	Tablet	8910	2851
383	Norfloxacin Tab. 400mg	Norfloxacin 400 mg Tab	Tablet	18434025	24480385
384	Nor-Triptyline Tablet 10mg	Nor-Triptyline Tablet 10mg	Tablet	8910	44906
385	Nor-Triptyline Tablet 50mg	Nor-Triptyline Tablet 50mg	Tablet	8910	44906
386	Ofloxacin Tab 200mg	Ofloxacin 200 mg Tab	Tablet	13269060	29187686
387	Olanzapine Tab 10mg	Olanzapine 10 mg Tab	Tablet	247500	73260
388	Olanzapine Tab 5mg	Olanzapine 5 mg Tab	Tablet	38455920	11782894
389	Omega-3 fish oil capsule	Each Capsule contains Omega-3 (370mg) EPA (207.90 mg) DHA (138.60 mg)	Capsule	9000	216000

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
390	Omeprazole Cap 40 mg	Omeprazole 40 mg Cap	Capsule	117000	70200
391	Omeprazole Capsule 20 mg	Omeprazole 20 mg Cap	Capsule	390550725	162469102
392	Ondansetron Tab I.P 4mg	Ondansetron 4 mg Tab	Tablet	180439425	42583704
393	Oseltamivir 30 mg Tab	Oseltamivir 30 mg Tab	Tablet	3375	20520
394	Oseltamivir 45 mg Tab	Oseltamivir 45 mg Tab	Tablet	1000	11680
395	Oseltamivir 75 mg Tab	Oseltamivir 75 mg Tab	Tablet	94050	1194059
396	Oxcarbazepine 150mg Tablet	Oxcarbazepine 150mg Tablet	Tablet	4500	72000
397	Pantoprazole 20 mg Tab	Pantoprazole 20 mg Tab	Tablet	675000	264600
398	Pantoprazole Tab. 40mg	Pantoprazole 40 mg Tab	Tablet	19200375	6313083
399	Para-amino salicylic acid Tablet 500 mg	Para-amino salicylic acid Tablet 500 mg	Tablet	8910	29225
400	Paracetamol Tab 250mg	Paracetamol Tab 250mg	Tablet	267308910	51323311
401	Paracetamol Tab 500mg	Paracetamol 500mg Tab	Tablet	143180123 2	355086705
402	Paracetamol Tab 650mg	Paracetamol 650 mg Tab	Tablet	61257150	24747889
403	Paracetamol Tablet 100 mg	Paracetamol Tablet 100 mg	Tablet	89100	13543
404	Pentoxifylline Tab 400mg	Pentoxifylline 400 mg Tab	Tablet	2250	5184
405	Phenobarbitone Tab 30mg	Phenobarbitone 30 mg Tab	Tablet	3951083	1027282
406	Phenobarbitone Tab 60mg	Phenobarbitone 60 mg Tab	Tablet	8430480	4046630
407	Phenytoin Sodium ER Tablet 300 mg	Phenytoin Sodium ER Tablet 300 mg Aluminium Blister - Strip of 10 Tab	Tablet	278910	223128

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
408	Phenytoin Tab 100mg	Phenytoin Sodium 100 mg Tab	Tablet	26551710	7540686
409	Phenytoin Tab 300mg	Tab. Phenytoin Sodium 300 mg	Tablet	8910	10692
410	Phenytoin Tab 50mg	Tab. Phenytoin Sodium 50 mg	Tablet	548910	2311570
411	Phenytoin Tablet 500 mg	Phenytoin Tablet 500 mg	Tablet	891000	1496880
412	Phytomenadione (Vitamin K1) Tablet 10 mg	Phytomenadione (Vitamin K1) Tablet 10 mg	Tablet	16360110	56278778
413	Polyvitamin (Therapeutic) NFI Tab	Polyvitamin (Therapeutic) NFI Tab	Tablet	6750000	19322820
414	Prazosin 2.5 mg	Prazosin 2.5 mg SR Tab	Tablet	20250	154710
415	Pre and Probiotic Capsule	Each Capsule contains: Streptococcus Faecalis T-110JPC 60 Million, Clostridium Butyricum TO-A 4 Million, Bacillus Mesentericus TO-A JPC 2 Million, Lactic Acid Bacillus 100 Million (Lactobacillus Sporogenes)	Capsule	31500	219492
416	Prednisolone Tab 10 mg	Prednisolone 10 mg Tab	Tablet	967500	843660
417	Prednisolone Tab 20mg	Prednisolone 20 mg Tab	Tablet	70875	120771
418	Prednisolone Tab 5mg	Prednisolone Tab 5mg	Tablet	9024563	4115201
419	Prednisolone Tablet 10 mg	Prednisolone Tablet 10 mg	Tablet	6961842	3011414
420	Pregabalin 75mg +Methylcobalamin 750mcg Cap	Each hard gelatine capsule contains Pregabalin 75mg + Methylcobalamin 750mcg Cap	Capsule	373500	481905
421	Pregabalin 75mg Capsule	Pregabalin 75mg Capsule	Capsule	213750	335160
422	Pregabalin Tablet 150mg	Pregabalin Tablet 150mg	Tablet	1213110	1164586
423	Pregabalin Tablet 25mg	Pregabalin Tablet 25mg	Tablet	8910	4093

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
424	Primaquine Tab 15mg	Primaquine Tab 15mg, Aluminium Blister Strip of 10 Tablet	Tablet	3506400	6045034
425	Primaquine Tab 2.5mg	Primaquine Tab 2.5mg, Aluminium Blister Strip of 10 Tablet	Tablet	1307250	460152
426	Primaquine Tab 7.5mg	Primaquine Tab 7.5mg, Aluminium Blister Strip of 10 Tablet	Tablet	2334375	1820813
427	Propranolol HCL 10 mg Tab	Propranolol HCL 10 mg Tab	Tablet	1679042	906683
428	Propranolol Tab 40 mg	Propranolol 40 mg Tab	Tablet	350910	226604
429	Propranolol Tablet 5 mg	Propranolol Tablet 5 mg	Tablet	8910	1308
430	Pyridoxine Tab 10 mg	Pyridoxine 10 mg Tab	Tablet	125100	16013
431	Pyridoxine Tab 50 mg	Pyridoxine 50 mg Tab	Tablet	7650	4774
432	Quetiapine Tab 100 mg	Quetiapine 100 mg Tab	Tablet	292500	224640
433	Quetiapine Tab 50mg	Quetiapine 50 mg Tab	Tablet	528750	304560
434	Quinine Sulphate Tab. 300mg	Tab. Quinine Sulfate 300 mg, Aluminium Blister Strip of 10 Tablet	Tablet	15390	52942
435	Rabeprazole 20 mg Tab	Rabeprazole 20 mg Tab	Tablet	168750	243000
436	Ramipril Tab 2.5mg	Ramipril Tab 2.5mg	Tablet	1088910	522677
437	Ramipril Tab 5mg	Ramipril Tab 5mg	Tablet	1241910	680567
438	Ranitidine 300 mg Tab	Ranitidine 300 mg Tab	Tablet	112500	63000
439	Ranitidine Tablet 150mg	Tab. Ranitidine Hydrochloride 150 mg Aluminium Blister - Strip of 10 Tablets	Tablet	429150150	218008276
440	Riboflavin Tab 5mg	Riboflavin Tab 5mg	Tablet	2786130	2897575
441	Rifabutin 150 mg Capsule	Cap Rifabutin 150 mg, Strip of 10 Capsule	Capsule	8910	114048

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
442	Rifaximin tablet 400mg	Rifaximin tablet 400mg	Tablet	58500	1558440
443	Risperidone Tab 2mg	Risperidone Tablet 2 mg	Tablet	27041670	6273667
444	Ritonavir Cap 100mg	Ritonavir Cap 100mg	Capsule	8910	121176
445	Rosuvastatin 20mg Tab	Rosuvastatin 20mg Tab	Tablet	193500	300312
446	Salbutamol 2 mg Tab	Salbutamol 2 mg Tab	Tablet	9370485	1049494
447	Salbutamol Tab 4mg	Tab.Salbutamol Sulphate 4 mg Aluminium Blister - Strip of 10 Tab	Tablet	9971550	1954424
448	Senna Tablet,Granules,Powder	Senna Tablet,Granules,Powder 7.5 mg	Tablet	270891	40091868
449	Serratiopeptidase 15mg tablet	Tab Serratiopeptidase 15 mg	Tablet	15750	25200
450	Serratiopeptidase 5mg Tab.	Each Tab/Cap Contain: Serratiopeptidase 5 mg (10,000 Units Of Serratiopeptidase)	Tablet	85500	48564
451	Sertraline Tab 50mg	Sertraline 50 mg Tab	Tablet	2135250	751608
452	Sitagliptine Tab 100 mg	Sitagliptin 100 mg Tab	Tablet	175500	228318
453	Soda Mint 300 mg Tablet	Tablet Soda Mint 300 mg	Tablet	23625	39690
454	Sodium Aminosaliclylate granules 10gm	Sodium Aminosaliclylate granules 10gm	Tablet	1000	6400
455	Sodium Aminosaliclylate granules 9.2gm	Sodium Aminosaliclylate granules 9.2gm	Tablet	1000	5824
456	Sodium bicarbonate 500mg Tab	Sodium bicarbonate 500mg Tab	Tablet	140180	484460
457	Sodium Valproate 134mg + Valporic Acid 58 mg CR Tab	Sodium Valproate 134mg + Valporic Acid 58 mg CR Tab	Tablet	337500	864000
458	Sodium Valproate Tab 200mg	Sodium Valproate Tab 200mg, Strip of 10 Tablets	Tablet	30133913	28410253
459	Sodium Valproate Tab 250mg	Sodium Valproate Tab 250mg, Strip of 10 Tablets	Tablet	8910	8554

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
460	Sodium Valproate Tab 500mg	Sodium Valproate Tab 500mg, Strip of 10 Tablets	Tablet	4931010	6548381
461	Sodium Valproate Tablet 100mg	Sodium Valproate Tablet 100mg, Strip of 10 Tablets	Tablet	8910	9979
462	Sodium Valproate Tablet 300mg	Sodium Valproate Tablet 300mg, Strip of 10 Tablets	Tablet	8910	10692
463	Spironolactone Tab 25 mg	Spironolactone 25 mg Tab	Tablet	604620	880327
464	Spironolactone Tab 50mg	Tab Spironolactone 50 mg Aluminium Blister - Strip of 10 Tab	Tablet	667620	1228421
465	Sucralfate 10 mg Tablet	Sucralfate 10 mg Tablet, Strip of 10 Tablets	Tablet	5408910	12548671
466	Sulfasalazine Tablet 500mg	Sulfasalazine Tablet 500mg, Strip of 10 Tablets	Tablet	60822	184899
467	Sumatriptan Tab 25mg	Sumatriptan Tab 25mg, Strip of 10 Tablets	Tablet	58736	204402
468	Tab Co-trimoxazole	Cotrimoxazole SS (Trimethoprim 80mg + Sulphamethoxazole 400mg) Tab	Tablet	12096000	6531840
469	Tab Co-trimoxazole DS	Cotrimoxazole DS (Trimethoprim 160mg+ Sulphamethoxazole 800mg) Tab	Tablet	8172270	9410532
470	Tab Co-trimoxazole Paed	Tab. Cotrimazole (Trimethoprim + Sulphametaxazole) Paed Tab. Cotrimoxazole (Trimethoprim 20 mg + Sulphametaxazole 100 mg) Paed , Strip of 10 Tablets	Tablet	40090660	14111912
471	Tab Glibenclamide 5mg + Metformin 500mg	Glibenclamide 5mg + Metformin 500mg Tab	Tablet	5625	4950
472	Tab Prazocin 5 mg	Prazosin 5 mg SR Tab	Tablet	148500	645084
473	Tab Tacrolimus 1mg	Tacrolimus 1mg Tab	Tablet	2250	16830
474	Tab Tamsulocin 0.4 mg	Tamsulosin 0.4 mg Tab	Tablet	231975	155887
475	Tab. Chlorthalidone 12.5mg	Chlorthalidone 12.5mg Tab	Tablet	171000	84269
476	Tab. Glyceryl Trinitrate 2.6mg	Each CR Tab/Cap to contain : Glyceryl Trinitrate 2.6mg.	Tablet	147375	122616

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
477	Tab. Sodium Valproate 500mg	Sodium Valproate 500 mg Tab	Tablet	844875	1209861
478	Tab. Telmisartan 40 mg	Telmisartan 40 mg Tab	Tablet	7846875	2521044
479	Tab.Glimepiride 1 mg	Glimepiride 1 mg Tab	Tablet	3087000	469224
480	Tablet Artemether (A) 20mg + Lumefantrine (B) 120mg	Artemether (A) + Lumefantrine (B)Tablet contains; Artemether (A) 20 mg (A) + Lumefantrine (B) 120 mg (B), Strip of 6 Tablets	Tablet	5346	11975
481	Tablet Artemether (A) 40mg + Lumefantrine (B) 240mg	Artemether (A) + Lumefantrine (B)Tablet contains; Artemether (A) 40 mg (A) + Lumefantrine (B) 240 mg (B), Strip of 6 Tablets	Tablet	77598	327153
482	Tablet Artemether (A) 80mg + Lumefantrine (B) 480mg	Artemether (A) + Lumefantrine (B)Tablet contains; Artemether (A) 80 mg (A) + Lumefantrine (B) 480 mg (B), Strip of 6 Tablets	Tablet	77598	527046
483	Tablet Bedaquiline - 100mg	Tablet Bedaquiline 100mg, Strip of 10 Tablets	Tablet	1213110	97048800
484	Tablet Calcium Carbonate 650 mg equivalent to Elemental Calcium 250 mg and Cholecalciferol USP 125mg	Tablet Calcium Carbonate 650 mg equivalent to Elemental Calcium 250 mg and Cholecalciferol USP 125mg	Tablet	27008910	49696394
485	Tablet Capecitabine 500mg	Tablet Capecitabine 500mg, Strip of 10 Tablets	Tablet	9180	1517638
486	Tablet Captopril 25mg	Tablet Captopril 25mg, Strip of 10 Tablets	Tablet	8910	4206
487	Tablet Chlorthalidone 12.5mg	Tablet Chlorthalidone 12.5mg, Strip of 10 Tablets	Tablet	16877700	18903024
488	Tablet Chlorthalidone 6.25mg	Chlorthalidone 6.25mg Tab	Tablet	327375	112617
489	Tablet Clarithromycin 250 mg	Tablet Clarithromycin 250 mg, Strip of 10 Tablets	Tablet	1213110	43613731
490	Tablet Clarithromycin 500 mg	Clarithromycin 500 mg Tab	Tablet	20160	192972
491	Tablet Clonidine 100mcg	Tablet Clonidine 100mcg, Strip of 10 Tablets	Tablet	145530	9925146
492	Tablet Delamanid 50mg	Tablet Delamanid 50mg, Strip of 10 Tablets	Tablet	1204200	1637712

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
493	Tablet Digoxin 250 mcg	Tab. Digoxin 250 microgram i.e.0.25 mg, Strip of 10 Tab	Tablet	165240	85925
494	Tablet Ethambutol 100 mg	Tablet Ethambutol 100 mg, Strip of 10 Tablets	Tablet	1213110	863734
495	Tablet Ethambutol 200 mg	Tablet Ethambutol 200 mg, Strip of 10 Tablets	Tablet	1213110	1213110
496	Tablet Ethambutol 400 mg	Tablet Ethambutol 400 mg, Strip of 10 Tablets	Tablet	1213110	1470095
497	Tablet Ethambutol 600 mg	Tablet Ethambutol 600 mg, Strip of 10 Tablets	Tablet	1213110	1611010
498	Tablet Ethambutol 800 mg	Tablet Ethambutol 800 mg, Strip of 10 Tablets	Tablet	1213110	2038025
499	Tablet Ethionamide 125 mg	Tablet Ethionamide 125 mg, Strip of 10 Tablets	Tablet	1213110	970488
500	Tablet Ethionamide 250 mg	Tablet Ethionamide 250 mg, Strip of 10 Tablets	Tablet	1213110	4076050
501	Tablet Etophyllin 231mg + Theophyllin 69mg SR	Tab. Etophyllin 231 mg + Theophyllin 69 mg S R Aluminium Blister , Strip of 10 Tablets	Tablet	10632600	8761262
502	Tablet Favipiravir 200 mg	Tablet Favipiravir 200 mg, Strip of 10 Tablets	Tablet	8910	144342
503	Tablet Favipiravir 400 mg	Tablet Favipiravir 400 mg, Strip of 10 Tablets	Tablet	8910	249480
504	Tablet Gliclazide 40 mg	Tablet Gliclazide 40 mg, Strip of 10 Tablets	Tablet	5408910	4327128
505	Tablet Glipizide 5mg	Glipizide 5mg Tab	Tablet	6750	10800
506	Tablet Glyceryl Trinitrate Sublingual 0.5 mg	Tab. Glyceryl Trinitrate 0.5 mg, Strip of 10 Tablets	Tablet	278910	334692
507	Tablet Hydrochlorthiazide 12.5 mg	Tablet Hydrochlorthiazide 12.5 mg, Strip of 10 Tablets	Tablet	49950	13187
508	Tablet Hydrochlorthiazide 25 mg	Tablet Hydrochlorthiazide 25 mg, Strip of 10 Tablets	Tablet	44550	19958
509	Tablet Hydrochlorthiazide 50 mg	Tablet Hydrochlorthiazide 50 mg, Strip of 10 Tablets	Tablet	44550	21384

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
510	Tablet IFA containing 45 mg Elemental Iron & 400 mcg Folic Acid	Tablet IFA containing 45 mg Elemental Iron & 400 mcg Folic Acid, Strip of 10 Tablets	Tablet	13643100	7334531
511	Tablet Isoniazid 100 mg	Tablet Isoniazid 100 mg Strip of 10 Tablets	Tablet	1213110	756981
512	Tablet Isoniazid 300 mg	Tablet Isoniazid 300 mg Strip of 10 Tablets	Tablet	1213110	1339273
513	Tablet Isoniazid 50 mg	Tablet Isoniazid 50 mg, Strip of 10 Tablets	Tablet	8910	4419
514	Tablet Isoniazid 75 mg	Tablet Isoniazid 75 mg, Strip of 10 Tablets	Tablet	8910	4847
515	Tablet Letrozole 2.5mg	Letrozole 2.5mg Tab	Tablet	11660	125689
516	Tablet Levocetirizine 10 mg	Tablet Levocetirizine 10 mg contains; Levocetirizine Dihydrochloride 10 mg, Strip of 10 Tablets	Tablet	138130245	22100839
517	Tablet Levocetirizine 5 mg	Tablet Levocetirizine 5 mg, Strip of 10 Tablets	Tablet	27510300	3263822
518	Tablet Levofloxacin 250mg	Tablet Levofloxacin 250mg, Strip of 10 Tablets	Tablet	1213110	3202610
519	Tablet Levofloxacin 500mg	Tablet Levofloxacin 500mg, Strip of 10 Tablets	Tablet	1213110	3202610
520	Tablet Levofloxacin 500mg	Levofloxacin 500mg Tab	Tablet	65250	78300
521	Tablet Levofloxacin 750 mg	Tablet Levofloxacin 750 mg, Strip of 10 Tablets	Tablet	1213110	8249148
522	Tablet Levonorgestrel 0.75mg	Tablet Levonorgestrel 0.75mg, Strip of 10 Tablets	Tablet	189540	10614240
523	Tablet Medroxyprogesterone 5 mg	Medroxyprogesterone 5mg Tab	Tablet	9360	45452
524	Tablet Methotrexate 2.5mg	Methotrexate 2.5mg Tab	Tablet	13410	74023
525	Tablet Methotrexate 7.5mg	Tablet Methotrexate 7.5mg, Strip of 10 Tablets	Tablet	9018	7214
526	Tablet Methyldopa 250mg	Tablet Methyldopa 250mg, Strip of 10 Tablets	Tablet	1088910	6533460

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
527	Tablet Methyldopa 500mg	Tablet Methyldopa 500mg, Strip of 10 Tablets	Tablet	548910	1427166
528	Tablet Montelukast 10 mg	Tablet Montelukast 10 mg, Strip of 10 Tablets	Tablet	16794947	27274994
529	Tablet Montelukast 5 mg	Tablet Montelukast 5 mg, Strip of 10 Tablets	Tablet	27089100	34890761
530	Tablet Moxifloxacin 400 mg	Tablet Moxifloxacin 400 mg, Strip of 10 Tablets	Tablet	1213110	15634562
531	Tablet Moxifloxacin 500 mg	Tablet Moxifloxacin 500 mg, Strip of 10 Tablets	Tablet	1204200	19267200
532	Tablet Naltrexone 50mg	Tablet Naltrexone 50mg, Strip of 10 Tablets	Tablet	365175	28279152
533	Tablet Ofloxacin 400 mg	Tablet Ofloxacin 400 mg, Strip of 10 Tablets	Tablet	4048695	297983952
534	Tablet Ormeloxifene 30 mg	Tablet Ormeloxifene 30 mg, Strip of 10 Tablets	Tablet	8910	769824
535	Tablet Penicillin V (Phenoxymethyl Penicillin) 250mg	Tablet Penicillin V (Phenoxymethyl Penicillin) 250mg	Tablet	8910	34571
536	Tablet Pyrazinamide 150 mg	Tablet Pyrazinamide 150 mg, Strip of 10 Tablets	Tablet	8910	4134
537	Tablet Pyrazinamide 400 mg	Tablet Pyrazinamide 400 mg, Strip of 10 Tablets	Tablet	8910	12118
538	Tablet Pyrazinamide 500 mg	Tablet Pyrazinamide 500 mg, Strip of 10 Tablets	Tablet	1213110	1843927
539	Tablet Pyrazinamide 750 mg	Tablet Pyrazinamide 750 mg, Strip of 10 Tablets	Tablet	1213110	2232122
540	Tablet Pyridoxine 100 mg	Tablet Pyridoxine 100 mg, Strip of 10 Tablets	Tablet	1213110	737571
541	Tablet Pyridoxine 25 mg	Tablet Pyridoxine 25 mg, Strip of 10 Tablets	Tablet	8910	1212
542	Tablet Pyridoxine 40 mg	Tablet Pyridoxine 40 mg, Strip of 10 Tablets	Tablet	1213110	194098
543	Tablet Pyridoxine 50 mg	Tablet Pyridoxine 50 mg, Strip of 10 Tablets	Tablet	1213110	213507
544	Tablet Rifampicin 150mg	Tablet Rifampicin 150mg, Strip of 10 Tablets	Tablet	1213110	2038025

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
545	Tablet Rifampicin 300 mg	Tablet Rifampicin 300 mg, Strip of 10 Tablets	Tablet	1213110	2232122
546	Tablet Rifampicin 450mg	Tablet Rifampicin 450mg, Strip of 10 Tablets	Tablet	1213110	2503859
547	Tablet Rifampicin 600mg	Tablet Rifampicin 600mg, Strip of 10 Tablets	Tablet	1213110	2911464
548	Tablet Rifampicin 75mg	Tablet Rifampicin 75mg, Strip of 10 Tablets	Tablet	1213110	1649830
549	Tablet Seratiopeptidase 10mg	Tablet Seratiopeptidase 10mg, Strip of 10 Tablets	Tablet	16974900	17382298
550	Tablet Sildenafil 50 mg	Sildenafil 50mg Tab	Tablet	8438	108000
551	Tablet Sofosbuvir 400mg	Tablet Sofosbuvir 400mg, 28 Tablet Tin	Tablet	75600	7862400
552	Tablet Tamoxifen 10mg	Tablet Tamoxifen 10mg, Strip of 10 Tablets	Tablet	8910	15682
553	Tablet Tamoxifen 20mg	Tablet Tamoxifen 20mg, Strip of 10 Tablets	Tablet	1000	3560
554	Tablet Telmisartan 40mg	Tablet Telmisartan 40mg, Strip of 10 Tablets	Tablet	935744400	300703334
555	Tablet Theophylline ER 400 mg	Tablet Theophylline ER 400 mg, Strip of 10 Tablets	Tablet	8910	203148
556	Tablet Thiamine 100 mg	Tablet Thiamine 100 mg, Strip of 10 Tablets	Tablet	764910	8768928
557	Tablet Trifluoperazine 5mg + Trihexyphenidyl 2mg	Trihexyphenidyl 2 mg + Trifluoperazine 5 mg Tab	Tablet	3858750	1728720
558	Tamoxifen Citrate Tab 20 mg	Tamoxifen citrate 20mg Tab	Tablet	1125	1638
559	Tapentadol Tablet 25mg	Tapentadol Tablet 25mg	Tablet	52740	1265760
560	Tenofovir 300mg + Lamivudine 300mg + Efavirenz 600mg (FDC)	Tenofovir 300mg + Lamivudine 300mg + Efavirenz 600mg (FDC)	Tablet	5006	148185
561	Tenofovir Alafenamide Fumarate 25mg (TAF)	Tenofovir Alafenamide Fumarate 25mg (TAF)	Tablet	378000	6652800
562	Tenofovir Disoproxil Fumarate (TDF) 300 mg	Tenofovir Disoproxil Fumarate (TDF) 300 mg	Tablet	2268000	22861440

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
563	Tetracycline 500 mg Cap	Tetracycline 500 mg Cap	Capsule	2250	4032
564	Thalidomide 100mg Capsule	Thalidomide 100mg Capsule	Capsule	1000	12200
565	Theophylline 300 mg Tab	Theophylline 300 mg Tab	Tablet	112500	1130400
566	Thiocolchicoside 4 mg Cap	Thiocolchicoside 4 mg Cap	Capsule	180000	495360
567	Thymol	IP	Tablet	1000	1600000
568	Thyroxine sodium 100 mcg Tab	Thyroxine sodium 100 mcg Tab	Tablet	302063	89386
569	Thyroxine sodium 50 mcg Tab	Thyroxine sodium 50 mcg tab	Tablet	855000	273600
570	Thyroxine Sodium 75 mcg Tab	Thyroxine Sodium 75 mcg Tab	Tablet	11250	3960
571	Thyroxine Sodium Tab 25 mcg	Thyroxine sodium 25 mcg Tab	Tablet	239625	74763
572	Ticagrelor 90 mg	Each Tab/Cap to contain:Ticagrelor 90mg	Tablet	1000	12336
573	Tinidazole Tab. 300mg	Tinidazole 300 mg Tab	Tablet	12325410	6507816
574	Tinidazole Tab. 500mg	Tinidazole Tab. 500mg, Strip of 10 Tablets	Tablet	2421765	871835
575	Tolperisone + Diclofenac Tab	Each film coated Tab/Cap to contain: Tolperisone Hydrochloride JP 150mg + Diclofenac Sodium IP 50mg, Excipients q.s	Tablet	22500	108900
576	Torsemide 10mg Tablet	Torsemide 10mg Tablet	Tablet	13500	16200
577	Tramadol Capsule 100 mg	Tramadol Capsule 100 mg, Strip of 10 Capsules	Capsule	896445	1702815
578	Tramadol Tab. 50mg	Tramadol 50 mg Tab	Tablet	3034260	5710720
579	Tranexemic Acid Tablet 500mg	Tranexamic Acid 500 mg Tab	Tablet	1106865	6264856

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
580	Trifluoperazine 5 mg Tab	Trifluoperazine 5 mg Tab	Tablet	1248750	492307
581	Trihexyphenidyl 2mg Tab	Trihexyphenidyl 2mg Tab	Tablet	2621250	1691021
582	Trihexyphenidyl Hydrochloride Tab 2mg	Tab. Benzhexol (Trihexyphenidyl) 2 mg, Strip of 10 Tablets	Tablet	18753451	2250414
583	Trypsin + Chymotrypsin E C 100000 IU Aluminium Blister of 10 Tab	Trypsin + Chymotrypsin E C 100000 IU Aluminium Blister of 10 Tab	Tablet	15214950	38743349
584	Ursodeoxycholic Acid Tab 150mg	Ursodeoxycholic Acid Tab 150mg	Tablet	115875	1362690
585	Verapamil Tab 120mg	Verapamil Tab 120mg, Strip of 10 Tablets	Tablet	8910	22810
586	Verapamil Tab 40mg	Verapamil Tab 40mg, Strip of 10 Tablets	Tablet	8910	19958
587	Viglibose Tab 0.2 mg	Voglibose 0.2 mg Tab	Tablet	22500	10260
588	Vildagliptin 50 mg Tab	Vildagliptin 50 mg Tab	Tablet	292500	3582540
589	Vitamin A 100000 IU Cap	Vitamin A 100000 IU Cap	Capsule	1125	2304
590	Vitamin A Capsule 50000 IU	Vitamin A Capsule 50000 IU, Srip of 10 Capsules	Capsule	5038407	6046088
591	Vitamin B Complex (Therapeutic) NFI Tab	Vitamin B Complex (Therapeutic) NFI Tab	Tablet	21791250	5076490
592	Vitamin B Complex, Vitamin C and Zinc Tablet	Each Tab/Cap to contain: Zinc Sulphate Monohydrate 61.8mg (eqv to Elemental Zinc 22.5mg), Ascorbic Acid (as coated) 150mg, Nicotinamide 50mg, Thiamine Mononitrate 10mg, Riboflavin 10mg, Calcium Pantothenate 10mg, Pyridoxine HCL 3mg, Folic Acid 1.5mg, Cyanocobalamin 10mcg	Tablet	742500	1508760
593	Vitamin D3 60000 IU Cap	Vitamin D3 60000 IU Cap	Capsule	67500	147798
594	Vitamin E 400iu Capsule	Vitamin E Acetate Equivalent to Vitamin E 400iu Capsule	Capsule	510750	1021500

Sr No.	Item Name	Specifications	Sub Category	Revised Proposed Qty.	Revised Avg. Turnover
595	Vitamin-A 25000 I.U. Cap	Vitamin-A 25000 I.U. Cap	Capsule	49500	107712
596	Vitamin B Complex Tablets N.F.I.	Tab. Vitamin B complex (Therapeutic) N F I, Strip of 10 Tablets	Tablet	946350000	219553200
597	Voglibose 0.3 mg Tab	Voglibose 0.3 mg Tab	Tablet	22500	9000
598	Voroconazole 200mg Tablet	tablet Voroconazole 200 mg	Tablet	1000	52000
599	Warfarin Sodium 5 mg Tab	Warfarin Sodium 5 mg Tab	Tablet	22500	52560
600	Warfarin Sodium Tab 1mg	Warfarin Sodium Tab 1mg, Strip of 10 Tablets	Tablet	129330	77598
601	Warfarin Sodium Tab 2mg	Warfarin Sodium Tab 2mg, Strip of 10 Tablets	Tablet	156330	125064
602	Warfarin Sodium Tab 3mg	Warfarin Sodium Tab 3mg, Strip of 10 Tablets	Tablet	8910	7128
603	Warfarin sodium Tablet 5mg	Warfarin sodium Tablet 5mg, Strip of 10 Tablets	Tablet	156330	125064
604	Zidovudine 300mg+ Lamivudine 150mg+ Nevirapine 200mg Tab	Zidovudine 300mg+ Lamivudine 150mg+ Nevirapine 200mg Tab	Tablet	8910	64152
605	Zidovudine Tab 300mg	Zidovudine Tab 300mg	Tablet	8910	66290
606	Zinc Sulphate 20 mg Each dispersible tablet contains Zinc Sulphate (as Monohydrate) 54.88mg equivalent to elemental Zinc 20mg Tab	Zinc Sulphate 20 mg Each dispersible tablet contains Zinc Sulphate (as Monohydrate) 54.88mg equivalent to elemental Zinc 20mg Tab	Tablet	578250	61988
607	Zinc Sulphate DT 20mg	Tab. Zinc Sulphate 20 mg Each Dispersible Tablet contains Zinc Sulphate (as Monohydrate) 54.88mg equivalent to elemental Zinc 20mg.	Tablet	48181500	5528615
608	Zinc Sulphate Tablet 10mg	Zinc Sulphate Tablet 10mg, Each Tablet contains Zinc Sulphate (as Monohydrate) 54.88mg equivalent to elemental Zinc 10mg.	Tablet	249868800	25986355
609	Zolpidem Tab 10mg	Tab. Zolpidem Tartrate 10 mg, Strip of 10 Tablets	Tablet	1524510	1939177

DRAFT

Appendix B: Checklist

(Mandatory Documents to be uploaded online in the EOI)

For the avoidance of any confusion, scanned copies of the above-mentioned documents shall be uploaded online on the Official Website on or prior to the EOI Due Date.

Sr. No.	DOCUMENTS.	Compliance	Page No. (as per the Bid)
1	Copy of certificate of incorporation/registration along with charter documents, and other registration documents according to the nature of entity	Yes / No	
2	Pan Card Details	Yes / No	
3	GST Registration certificate along with copy of the GST return of last quarter.	Yes / No	
4	Copy of manufacturing drug license with product list duly approved by the Licensing Authority/ State drug authority for each and every product quoted as per specification in the bid. The license must have been duly renewed up to date and the items quoted shall be clearly highlighted in the license	Yes / No	
5	World Health Organization-Good Manufacturing Practice certificate with either product list or COPP	Yes / No	
6	Copy of permission from DCGI for “New drug & Fixed Dose Combination”	Yes / No	
7	Market Standing Certificate as issued by Central or State Licensing Authority for relevant period against quoted Drugs	Yes / No	
8	Non-Conviction Certificate issued by Licensing Authority.	Yes / No	
9	Annexure-1 (Technical Specifications and Compliance)	Yes / No	
11	Annexure-2 (Undertaking by EOI Respondent)	Yes / No	
12	Annexure-3 (Proforma for Production and Sale Statement)	Yes / No	
13	Annexure-4 (Details of Manufacturing Unit)	Yes / No	

Sr. No.	DOCUMENTS.	Compliance	Page No. (as per the Bid)
14	Annexure-5 (Details of Items Quoted with Drug Code)	Yes / No	
15	Annexure-6 (Annual Turnover Statement for Three Years) along with Copies of Balance Sheet and Profit and Loss Accounts for last three years i.e., (2023-24, 2024-25 and 2025-26) certified by the Statutory Auditor or Chartered Accountant.	Yes / No	
16	Annexure-7 (Format for Power of Attorney for signing of EOI)	Yes / No	
17	Annexure-8 (Affidavit for Blacklisting)	Yes / No	
18	Annexure-9 (Litigation Affidavit)	Yes / No	
19	Annexure-10 (Mandate Form)	Yes / No	
20	Annexure -11 Delivery and Supply Capability	Yes / No	
21	Annexure-12 Respondent Classification	Yes / No	
22	Import Export Certificate (IEC Code) for Importer	Yes / No	
23	GST Registration certificate along with copy of the GST return of last quarter.	Yes / No	

Annexure 1: Technical Specifications and Compliance

Item Name: Following are the minimum requirements. Products offered must meet these parameters herein.

Sr. No	Item Name	Technical specification s/ composition of tender enquiry	Compliance on each parameter with detailed substantiation how the offered product meets the requirement.	If Column B=C (write Yes or No)	Generic Name / Brand Name (only for Importer)	Drug Mfg. License (Form 25 or 28 & 26)/ Medical devices/ Import License (Form 10 & 41)	MSM E/ SSI	Remarks, if any
	A	B	C	D	E	F	G	H

Note:

- Pharmacopoeia standards IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation quoted as per the provisions of the Applicable Laws.
- Active ingredient used in formulation of item quoted shall be of mentioned Pharmacopoeia quality & Specifications.

Sign

Stamp

Date

Annexure-2: Undertaking by EOI Respondent

To,
Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority,
1st Floor, Aarogya Bhawan,
Near CSMT Railway Station, Mumbai 400001 (Maharashtra)

Subject: EOI for the [*****]

Dear Sir,

With reference to your EOI dated _____, I, having examined the document and understood its contents, hereby submit my/our EOI for the aforesaid [*****]. The EOI is submitted voluntarily and without reservation, solely for market assessment purposes.

1. I/ We acknowledge that MMGPA will be relying on the information provided in the EOI and the documents accompanying such EOI, and we certify that all information provided therein is true and correct; nothing has been omitted which renders such information misleading; and all documents accompanying such EOI are true copies of their respective originals.
2. I/ We shall make available to MMGPA any additional information it may find necessary or require supplementing or authenticate the EOI.
3. I/ We declare that:
 - a) I/ We have examined and have no reservations to the EOI, including any Addendum / Corrigendum issued by MMGPA.
 - b) I/ We do not have any conflict of interest in accordance with the EOIs; and
 - c) I/We have not directly or indirectly or through an agent engaged or indulged in any unethical practice, as defined in the EOI, in respect of any tender or request for proposal issued by or any agreement entered into with MMGPA or any other public sector enterprise or any government, Central or State.
4. I/ We understand that this EOI is purely for market analysis purpose and you may not issue any following tender or empanelment process after this.
5. I/ We certify that we the Annual Turnover and Net Worth given by us is correct to the best of our knowledge.
6. I/ We certify that in regard to matters other than security and integrity of the country, we or any of our associates have not been convicted by a Court of Law or indicted or adverse orders passed by a regulatory authority which could cast a doubt on our ability to undertake the Contract or which relates to a grave offence that outrages the moral sense of the community.
7. I/ We further certify that in regard to matters relating to security and integrity of the country, we or any of our associates have not been charge-sheeted by any agency of the Government or convicted by a Court of Law.
8. I/ We further certify that no investigation which materially affects regulatory compliance or manufacturing/import operations is pending either against us or against our associates or against our CEO or any of our directors/ managers/ employees / Partners /Trustees.
9. I/We further certify that we or any of our Associates are not barred by the Central Government/ State Government or any entity controlled by it, from participating in any supply of drugs contract, and no bar subsists as on the EOI Due Date.

10. The power of attorney for signing of EOI, as per format provided at Annexure-6 of the EOI, is also enclosed.

In witness thereof, I/we submit this EOI under and in accordance with the terms of the EOI.

Yours faithfully,

Date:

(Signature, Name and designation of the Authorised signatory)

Place:

(Name and seal of Responder)

Annexure-3: Proforma for Production and Sale Statement

Name of the EOI Respondent entity:

Sr. No.	Year	Name and full Address of the Purchaser	Purchasing Entity (Gov./Semi Gov./Reg. under Trust)	Name of the Product	Purchase Order No. & Date	Purchase Order Quantity	Batch No.		PO Copy enclosed on Pg. No.
							Manufactured Qty	Sold Qty	
1	2023-24								
2	2024-25								
3	2025-26								

Add rows as per requirement.

Note:

1. In support of above statement, enclose the copies of supply orders and client's satisfactory certificates. All purchase orders should be enclosed in the serial as per the data provided in table above.
2. In case of importer, sold quantity shall be provided, production and manufactured good details may not be provided-
3. All the data of the bidding entity, as provided in the above table has been verified by undersigned Chartered Accountant/Statutory Auditor.
4. The issuer of this certificate must ensure that the above information/details are related to the bidding entity only.

Name, Membership number and signature of the Chartered Accountant/Statutory Auditor: UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name): Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure 4: Details of Manufacturing Unit

(The details of manufacturing facility to be furnished)

- 1 Name of the EOI Respondent :
- 2 Registered Office Address :
- 3 Manufacturing Unit Address :
- 4 PAN :
- 5 GST No. :
- 6 Manufacturing License No.:
- 7 Date of Issue :
- 8 Valid up to / Retention :
- 9 Issued by (SLA / CLA) :
- 10 WHO-GMP / Equivalent Certification:
 - a. Certifying Authority
 - b. Certificate Validity
- 11 Details of Installed Manufacturing Capability (Indicative)

Type	Indicative Capability Details
Tablets	
Capsules	
Injections	
IV Fluids	
Sterile Powders	
Liquids / Syrups	
Ointments / Creams	
Other (specify)	

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Signature of Authorized Signatory :

Name :

Designation :

Date :

Place :

Details of Installed Production Capacity for 30 days
(In Terms of Unit Packs)

Tablets :

Capsules:

General:

Beta-Lactum :

Injection

Ampoules :

Vials :

I.V.Fluids :

Sterile Powder:

Liquids

Suspension :

Syrups :

Drops :

Ointment :

Powders :

Antiseptics/

Disinfectants :

Name & designation of the authorized signatory:

Specimen signature of the authorized Signatory:

*The details of manufacturing unit should be for the premises where drugs quoted are actually manufactured.

THE DETAILS OF FACTORY PREMISES

Person In-charge of Factory

Name :

Phone No. :

Mobile No. :

Nearest Landmark of Factory:

Layout

Km from Airport :

Name of the Airport and City:

Km from Railway Station :

Name of the Railway Station :

Km from Bus Stand :

Name of the Bus Stand :
And City

All the data provided in the above table has been verified by undersigned Chartered Accountant/Statutory Auditor.

Name, Membership number and signature of the Chartered Accountant/Statutory Auditor: UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name): Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure-4 (A): Proof of Distribution Network

A. Distribution / Logistical Details

S.No	Particulars	Details
1	Whether distribution/logistics arrangement exists	Yes / No
2	Nature of arrangement (Own / Third-party / Proposed)	
3	Broad geographic coverage	
4	Presence in Maharashtra (if any)	Yes / No
5	Any other relevant details	

B. Authorised Distributors / Logistic Partners (If Applicable)

Sr. No.	Name	Address
1		
2		

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Signature of Authorized Signatory :

Name :

Designation :

Date :

Place :

Annexure-5: Details of Items Quoted with Drug Code

1. Name of the firm:
2. Address as given in drug licence:
3. Drug Licence No. in Form 25 &28:
4. Import Licence No. :
5. Date of issue:
6. Validity:
7. Non-conviction Certificate obtained on:
8. Market standing certificate obtained on:
9. Details of endorsement for all products:

Sr. No.	Drug name	Specifications IP/BP/USP	Date of endorsement obtained from State Drugs Commissioner	Whether Endorsement is in Generic or Brand Name

Add As Many Rows as possible You Want to Add

(Additional column should be inserted asking date of permission from CDSCO, in case of all newly introduced drugs and Fixed dose combinations)

Annexure 6: Annual Turnover Statement for Three Years

M/s. is participating in Tender No..... Items details as per Below Table.

Sr. No. of Item (as per Appendix A)	Name of Item	Required Turnover (In Rs)
Total Required Turnover		

The Average Annual Turnover and Net Worth details of M/s _____ for participation under the Tender Document are given below and certified that the statement is true and correct.

Sr. No.	Year	Turnover (In Rs.)
1		
2		
3		
4		
Net Worth		
5	Net worth in the latest financial year preceding the Bid Due Date (positive/negative)	

“Net Worth” in case of Company shall mean the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

For other eligible entities, the Net Worth shall mean the amount derived by subtracting the liabilities from the assets as certified by the chartered accountant/statutory auditor having valid registration.

Note:

1. Certificate issued by a statutory auditor/chartered accountant along with audited financial statements confirming the average annual turnover of the Bidder during the stated financial years must be submitted on the letterhead of the statutory auditor/chartered accountant.
2. Provide supporting audited financial statements (Balance Sheets, Profit and Loss Statements, etc.) of the bidding entity.
3. The Net Worth of the bidder in the financial year immediately preceding the Bid Due Date should be positive.
4. “Turnover” for the purposes of this Tender Document shall mean the monetary value of goods sold by the Bidder.

Name, Membership number and signature of the Chartered Accountant:

UDIN

Name and seal of the firm:

Location, Date:

Authorized Signature of Bidder (PoA holder)

[In full and initials with Seal]:

Name and Title of Signatory:

Name of Bidder (Firm/ Organization's name):

Address:

Telephone:

Email:

(Name and seal of the Bidder)

[Location, Date]

Annexure-7: Format for Power of Attorney for signing of EOI

(To be executed as an Affidavit on a Stamp paper of appropriate value)

Know all men by these presents, We, (name of the firm and address of the registered office) do hereby irrevocably constitute, nominate, appoint and authorize Mr. / Ms (Name), son/daughter/wife of..... and presently residing at, who is presently employed with us and holding the position of, as our true and lawful attorney (hereinafter referred to as the “**Attorney**”) to do in our name and on our behalf, all such acts, deeds and things as are necessary or required in connection with or incidental to submission of our EOI for the [*****], proposed or being developed by the [*****] (the “**Purchaser**”) including but not limited to signing and submission of all applications, EOIs and other documents and writings, participate in Responders' and other conferences and providing information / responses to MMGPA, representing us in all matters before MMGPA, signing and execution of all contracts including the Contract and undertakings consequent to acceptance of our EOI, and generally dealing with MMGPA in all matters in connection with or relating to or arising out of our EOI for the said Contract and/or upon award thereof to us and/or till the entering into of the Contract with MMGPA.

AND we hereby agree to ratify and confirm and do hereby ratify and confirm all acts, deeds and things done or caused to be done by our said Attorney pursuant to and in exercise of the powers conferred by this Power of Attorney and that all acts, deeds and things done by our said Attorney in exercise of the powers hereby conferred shall and shall always be deemed to have been done by us.

IN WITNESS WHEREOF WE, ..., THE
ABOVE-NAMED PRINCIPAL HAVE EXECUTED THIS POWER OF ATTORNEY ON
THIS
DAY OF, 20.....

For

(Signature, name, designation and address of person authorized by Board Resolution
in case of Firms/Company)/Partner in case of
Partnership Firms

Witnesses:

1.

2.

Notarised Person identified by me/personally appeared before me

/Signed before me/Attested/Authenticated* (*Notary to specify as applicable) (Signature, Name and Address of the Notary)

Seal of the Notary Registration Number of the Notary

Date__

Signature, name, designation and address of the Attorney)

Notes:

- The mode of execution of the Power of Attorney should be in accordance with the procedure, if any, laid down by the applicable law and the charter documents of the executants (s) and when it is so required, the same should be under common seal affixed in accordance with the required procedure.

Wherever required, the Responder should submit for verification the extract of the charter documents and documents such as a board or shareholders resolution/power of attorney in favour of the person executing this Power of Attorney for the delegation of power hereunder on behalf of the Responder.

- For a Power of Attorney executed and issued overseas, the document will also have to be legalized by the Indian Embassy and notarized in the jurisdiction where the Power of Attorney is being issued. However, the Power of Attorney provided by Responders from countries that have signed the Hague Legislation Convention, 1961 are not required to be legalized by the Indian Embassy if it carries a conforming Apostille certificate issued by the designated competent authority and has been notarized by the public notary.

Annexure-8: Undertaking for Non-blacklisting

(on Letterhead of the Respondent)

EOI reference No:E-283/MMGPA/ EOI for Tablets and Capsules (2026-27)

1. I/We, (Name of the Responder), the Responder herein, has not been found guilty of malpractices, misconduct or Blacklisted/Debarred/ deregistered for the quoted product by any department of Govt. of Maharashtra or by any local authority and semi Govt. organization and other State Government/Central Government's organizations/ procurement corporation as on the date of submission EOI for the quoted items.

4. I/We undertake that I/we are not involved in any major litigation such as fraud, FEMA violations and any other civil or criminal proceedings.

Seal

Signature of Authorized Signatory

Date

Place

Verification

I, the above named [*Name of the Responder*], do hereby solemnly verify that the contents of the above Affidavit are true and correct to my knowledge and belief. Nothing false has been stated therein or material concealed therefrom.

Verified at {*location*} on {*Date*}

Annexure- 9: Litigation Affidavit

(on Non-judicial Stamp Paper of Rs.500/-)

EOI reference No:E-283/MMGPA/ EOI for Tablets and Capsules (2026-27)

I _____ age _____ address (authorized signatory to sign the contract), hereby submit, vide this affidavit in truth, that I am the owner/authorized signatory of the bidding entity and I am submitting the documents in Envelope no.1 for the purpose of security of the contract. I hereby agree to the conditions mentioned below:-

1. I am liable for action under Bharatiya Nyaya Sanhita (BNS) for submission of any false/ fraudulent paper/information submitted in Envelope no.1
2. I am liable for action under Bharatiya Nyaya Sanhita (BNS) if during contract period and any false information, false bill of purchases supporting proof of purchase, proof of testing submitted by my staff, subletting company or by myself, I will be liable for action under Bharatiya Nyaya Sanhita (BNS).
3. I am liable for action under Bharatiya Nyaya Sanhita (BNS) if any paper is found false / fraudulent during contract period and even after the completion of contract (finalization of final bill).

Authorised Signature of Bidder

Seal of Company

Verification

I, the above named [*Name of the Bidder*], do hereby solemnly verify that the contents of the above Affidavit are true and correct to my knowledge and belief. Nothing false has been stated therein or material concealed therefrom.

Verified at {*location*} on {*Date*}

Annexure-10: Litigation Affidavit

01	Company Name	
02	Postal Address of the company with Telephone No., Fax No. and Mail address	
03	Name of the Managing Director/ Director/Manager Mobile No. /Phone No. E-mail address	
04	Name and designation of the authorized company official Mobile No. /Phone No. E-mail address	

Bank Details

01	Name of the Bank Branch Name & Address: Branch Code No. Branch Manager Mobile No. Branch Telephone no. Branch E-mail ID	
02	9-digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank.	
03	IFSC code of the Branch	
04	Type of Account (Current/Savings)	
05	Account Number (as appear in cheque book)	

(in lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars)

I/We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information, I would not hold Maharashtra Medical Goods Procurement Authority, Mumbai. I have read the conditions of tender/ agreement entered and agree to discharge the responsibility expected of me/from the company as a tenderer/ successful bidder.

Date

Company Seal

Signature

Place

(Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Bank Seal with address

Signature of the Authorized Official of the bank

Annexure 11: Delivery and Supply Capability

(To be submitted on the letterhead of the EOI Respondent)

This Annexure is intended to capture indicative information on the delivery readiness and supply capability of the EOI Respondent for the purpose of market assessment.

A. General Information

Name of the EOI Respondent: _____

Type (OEM / Authorized Importer): _____

Sr. No.	Parameter	Details
1	Average Production Lead Time (in days)	
2	Average Dispatch Time after production readiness (in days)	
3	Expected Delivery Timeline to Maharashtra (in days)	
4	Emergency Supply Capability (Yes/No, give details)	
7	Warehousing Facility in Maharashtra (Yes/No, location)	
8	Cold Chain Facility (if applicable)	
9	Logistics Arrangement (Own / Third-party / Hybrid)	
10	Any other relevant information	

Note: Submission of a physical Delivery Challan at the time of delivery is mandatory. The challan must bear the signature and seal of the authorized accepting authority; without such acknowledgment, the delivery shall not be treated as complete.

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Authorized Signatory

Name: _____

Designation: _____

Date: _____

Place: _____

Annexure 11 (a) : Delivery Acceptance Certificate

FINAL ACCEPTANCE CERTIFICATE

Date: / /2026.

To,
Chief Executive Officer,
Maharashtra Medical Goods Procurement Authority,
1st Floor, Aarogya Bhawan,
St. George's Hospital Compound, Mumbai 400001
Maha.mmgsa2023@gmail.com

Subject: Acceptance Certificate for the supply of

Reference: Purchase Order No.

As per above mentioned reference purchase order, the said material has been received by this office / hospital in good condition & as per terms & condition of the purchase order. The details of the same are as follows;

Sr. No.	Particular(s)	Specific information
1	Name of Material Received	
2	Quantity as per Purchase Order	
3	Invoice Number with Date	
4	Batch Number(s) with Quantity	
5	Total Quantity Received	
6	Date of Receipt of Material	
7	Entry Taken in Stock Book	
8	Stock Book No.	
9	Page Number	
10	Name of the Supplier	
11	Name of the Manufacturer	
12	Address of the Manufacturer as per Invoice	
13	Material Received as per Technical Specifications mentioned in Purchase Order (YES/NO)?	

**This is certifying that, the above information is true on the basis of office record.

Name of Pharmacist/ Store In-charge;

Name of Office/ Hospital In-charge;

(Signature with Stamp)

(Signature with Stamp)

Date:

Place:

Mail id for Acceptance: maha.mmgsa2023@gmail.com

84 | Page

EOI for Tablet and Capsules

Annexure 12: Respondent Classification Details

(To be submitted on the letterhead of the EOI Respondent)

This Annexure captures classification details for MSME status, social category, and geographical presence.

A. Basic Details

Sr. No.	Parameter	Details
1	Name of EOI Respondent	
2	Type of Entity (Company / LLP)	
3	Nature (OEM / Authorized Importer)	

B. Classification Details

Sr. No.	Parameter	Details
1	MSME Status (Yes/No)	
2	MSME Registration Number	
3	SC/ST Ownership (Yes/No)	
4	Certificate Details	

C. Classification

Sr. No.	Classification Parameter	Select One
1	Location Classification	☐ Within Maharashtra ☐ Outside Maharashtra
2	MSME Category	☐ MSME (Within Maharashtra) ☐ MSME (Outside Maharashtra) ☐ Non-MSME
3	SC/ST Category	☐ SC/ST (Within Maharashtra) ☐ SC/ST (Outside Maharashtra) ☐ Not Applicable

Declaration

I/We hereby declare that the information furnished above is true and correct to the best of my/our knowledge and belief.

Authorized Signatory

Name: _____

Designation: _____

Date: _____

Place: _____